tag:blogger.com,1999:blog-142343899163827172024-03-23T05:14:44.029-05:00THE INTERNATIONAL BLOG OF SURGERY<em>Heal with Steel!</em>Unknownnoreply@blogger.comBlogger38125tag:blogger.com,1999:blog-14234389916382717.post-46857719817267970002008-09-02T00:13:00.007-05:002008-09-02T03:11:27.552-05:00Bleeding Peptic Ulcer<a href="http://www.medscape.com/pi/editorial/cmecircle/2001/136/sung/slide03.gif"><img style="float:right; margin:0 0 10px 10px;cursor:pointer; cursor:hand;width: 320px;" src="http://www.medscape.com/pi/editorial/cmecircle/2001/136/sung/slide03.gif" border="0" alt="" /></a><br /><a><strong>What proportion of UGI Bleeds have a non-variceal cause?</strong><br /><blockquote>80-90%</blockquote></a><br /><p><br /></p><br /><a><strong>What are etiologic factors in the pathogenesis of peptic ulcers?</strong><br /><blockquote>Aspirin, NSAIDS, and <em>H. pylori</em></blockquote></a><br />Smoking tobacco also inhibits the gastric mucosal barrier...<br />Remember that gastric ulcers may be secondary to underlying malignancy.<p><br /></p><br /><a><strong>What are the types of gastric ulcers based on location?</strong><br /><blockquote>Type I - lesser curvature / incisura<br />Type II - incisura + duodenum<br />Type III - prepyloric<br />Type IV - high on lesser curvature near GE junction<br />Type V - anywhere, secondary to NSAIDs</blockquote></a><br /><p><br />Types II/III are classically attributed to acid hypersecretion<br /></p><br /><a><strong>What are common presenting symptoms associated with UGI Bleeding?</strong><br /><blockquote>Hematemesis<br />Melena<br />Hematochezia with fast/severe bleeds<br />Orthostatic changes<br />Syncope<br />Tachycardia<br />Hypotension</blockquote></a><br /><p><br /></p><br /><a><strong>What are initial steps of management of an UGI Bleed?</strong><br /><blockquote>Large-bore peripheral access<br />Type and Cross-match blood<br />Obtain CBC, electrolytes, BUN, Creatinine, INR, PTT<br />Volume Resuscitation with crystaloid<br />Monitored Unit<br />Insert NGT - Lavage<br />Urgent Upper Endoscopy</blockquote></a><br /><p><br /></p><br /><a><strong>What are you looking for with NG lavage?</strong><br /><blockquote>Aspiration of bloody or coffee-ground material.<br />A negative lavage is indicated by aspiration of bilious material.</blockquote></a><br /><p><br /></p><br /><a><strong>What is the Blatchford Score?</strong><br /><blockquote>A risk-stratification tool that predicts the need for medical intervention in patients presenting with UGI bleed. The scale ranges from 0-23.<br />(1) SBP: 100-109 (1 point), 90-99 (2 points), less than 90 (3 points)<br />(2) BUN: 6.5-7.9 (2 points), 8.0-9.9 (3 points), 10.0-24.9 (4 points), less than 25 (6 points)<br />(3) Hgb - men : 12.0-12.9 (1 point), 10.0-11.9 (3 points), less than 10(6 points).<br /> Hgb - women: 10.0-11.9 (1 point), less than 10 (6 points)<br />(4) Other variables: Tachycardia (1 point), Melena (1 point), Syncope (2 points), Hepatic disease (2 points), Cardiac failure (2 points) </blockquote></a><br /><p><br /></p><br /><a><strong>What is the Rockall score?</strong><br /><blockquote>A combination of clinical and endoscopic parameters that are used for risk-stratification of UGI bleed. The Scale ranges from 0-11 points.<br />CLINICAL :<br />-Age: Less tan sixty (0), 60-79y (1 point), over 80y (2 points)<br />-Shock: Tachycardia (1 point), SBP less than 100mmHg (2 points)<br />-Coexisting illness: Heart disease/CHF (2 points), Renal Failure, Hepatic Failure, or metastatic CA (3 points)<br />ENDOSCOPIC:<br />-Diagnosis: no lesion or Mallory Weiss tear (0), Peptic ulcer disease or esophagitis (1 point), UGI malignancy (2 points)<br />-Stigmata: Clean base, flat pigmented spot (0), UGI blood, active bleeding, visible vessel, or clot (2 points)</blockquote></a><br /><p><br /></p><br /><a><strong>What is the Forrest Classification?</strong><br /><blockquote>A classification of the likelihood of recurrent bleeding based on endoscopic appearance. <br />Grade IA - active spurting of blood<br />Grade IB - oozing of blood<br />Grade IIA - nonbleeding visible vessel<br />Grade IIB - adherent clot<br />Grade IIC - flat, pigmented spots<br />Grade III - clean-base ulcers</blockquote></a><br /><p>This is probably the only classification worth knowing... high risk lesions are Grades IA/B and IIA/B.<br /></p><br /><a><strong>What is the management of high-risk lesions?</strong><br /><blockquote>Endoscopic hemostasis<br /> - injection therapy (vasoconstrictors, sclerosants, tissue adhesives)<br /> - thermal therapy (heater probe, bipolar, argon plasma coagulation)<br /> - mechanical therapy (endoscopic clips, loops, suturing/stapling devices)<br />Testing for <em>H. pylori</em><br />Initiation of an IV proton pump inhibitor for 72 hrs, followed by an oral PPI<br />If hemodynamic stability is acheived, initiation of clear liquids 6 hrs after endoscopy.<br />Discontinuation of NSAIDS and antiplatelet agents.</blockquote></a><br />There is no strong data to support the use of octreotide in the management of non-variceal GI bleeding.<br /><p><br /></p><br /><a><strong>What is the management of low-risk lesions?</strong><br /><blockquote>Endoscopic hemostasis is not warranted<br />Start an oral PPI<br />Test for <em>H. pylori</em><br />Initiate clear liquids after 6hrs<br />Discontinuation of NSAIDS and antiplatelet agents</blockquote></a><br /><p><br /></p><br /><a><strong>What are predictors of re-bleeding?</strong><br /><blockquote>History of peptic ulcer disease<br />Prior ulcer bleeding<br />Presence of shock at presentation<br />Active bleeding during endoscopy<br />Large ulcers (greater than 2cm)<br />Large underlying bleeding vessel (greater than 2mm diamenter)<br />Ulcers on the lesser curvature of stomach<br />Ulcers on the posterior or superior duodenal bulb<br /></blockquote></a><br /><p><br /></p><br /><a><strong>What are the benefits of using proton-pump inhibitors?</strong><br /><blockquote>They significantly decrease the risk of ulcer rebleeding by 60%, the need for urgent surgery by 50%, and the risk of death by 57%.</blockquote></a><br /><p><br /></p><br /><a><strong>What is a non-operative option for addressing an acute GI bleed that has not been identified or controlled by endoscopy?</strong><br /><blockquote>Angiography with transcatheter embolization<br /> - Gelfoam, polyvinyl alcohol, cyanoacrylates, coils<br />Success ranges from 52-94%, with recurrent bleeding requiring repeated embolization in 10% of patients.</blockquote></a><br />In most institutions, this is reserved for endoscopic failures, especially in high-risk surgical candidates.<br /><p><br /></p><br /><a><strong>What is the operative management for a bleeding gastric ulcer?</strong><br /><blockquote>-Distal gastric resection to include the ulcer (Antrectomy)<br />-For Type II/III ulcers (hypersecretors), consider adding a vagotomy to the antrectomy... otherwise, long-term acid suppression<br />-In high risk patients, gastrotomy with wedge resection of ulcer, or oversewing and biopsy of the ulcer may be considered</blockquote></a><br />All patients should be tested for <em>H. pylori</em><br />Gastric ulcers should always be biopsied if not excised to rule out cancer.<br /><p><br /></p><br /><a><strong>What is a Pauchet procedure?</strong><br /><blockquote>An antrectomy with extension of the resection line to include the lesser curvature of the stomach in order to include an ulcer near the GE junction. A Billroth II gastrojejunostomy is commonly performed.</blockquote></a><br /><p><br /></p><br /><a><strong>What is a Csendes procedure?</strong><br /><blockquote>Resection of the gastric antrum and body up to the GE junction (subtotal gastrectomy). A Roux en Y gastrojejunostomy is performed along the resection line.</blockquote></a><br /><p><br /></p><br /><a><strong>What is a Kelling-Madlener procedure?</strong><br /><blockquote>An antrectomy, truncal vagotomy, and ulcer biopsies, while leaving a large GE junction/Type IV ulcer in place</blockquote></a><br /><p><br /></p><br /><a><strong>What is a Mallory Weiss tear?</strong><br /><blockquote>A linear mucosal tear at the GE junction.</blockquote></a><br /><p><br />Rarely do these require an operation...<br /></p><br /><a><strong>What is a Dieulafoy's lesion?</strong><br /><blockquote>An abnormal submucosal arteriole, usually in the proximal stomach, but can be anywhere in the GI tract.</blockquote></a><br /><p><br /></p><br /><a><strong>What is the etiology of bleeding duodenal ulcers?</strong><br /><blockquote>90% have <em>H. pylori</em> colonization of the antrum.<br />Massive bleeding is usually the result of transmural ulceration of the posterior duodenal wall, leading to erosion of the gastroduodenal artery.</blockquote></a><br /><p><br /></p><br /><a><strong>What is the operative management of a bleeding duodenal ulcer?</strong><br /><blockquote>Upper Midline Incision<br />Kocher maneuver to mobilize the duodenum medially<br />Longitudinal pyloromyotomy, extending 3cm on each side of the pylorus<br />Digital pressure of ulcer base to temporize bleeding<br />Allow resuscitation measures to catch up...<br />Suture ligation x2 of gastroduodenal artery proximal and distal to site of penetration<br />U-stitch (#3) is place medially in between to control the tranverse pancreatic branch...<br />Gastric antral biopsies for <em>H. pylori</em><br />Truncal Vagotomy and Pyloroplasty<br /><br />-some will forgo a V+P by controlling the ulcer through a longitudinal duodenotomy and medically treating the patient with PPIs and <em>H. pylori</em> eradication.<br />-An alternative operation that is the procedure of choice for a chronic bleeding duodenal ulcer is oversewing the ulcer then performing a V+A (truncal vagotomy and antrectomy).<br /></blockquote></a><br /><p>The risk of ulcer recurrence after a V+A is 2%, compared to 5% after a V+P.<br /></p><br /><a><strong>What is a Heineke-Mikulicz pyloroplasty?</strong><br /><blockquote>Transverse closure of the longitudinal incision</blockquote></a><br /><p><br /></p><br /><a><strong>What is a Finney pyloroplasty?</strong><br /><blockquote>Side to side closure of elongated pyloroduodenotomy</blockquote></a><br /><p><br /></p><br /><a><strong>What is a Jabouley pyloroplasty?</strong><br /><blockquote>A gastroduodenostomy</blockquote></a><br /><p><br /></p><br /><br />Late... SG<br /><br /><u>References</u>:<br />Gralnek IM, Barkun AN, Bardou M. Management of Acute Bleeding from a Peptic Ulcer. <em>NEJM</em> 2008; 359(9): 928-937.<br />Cameron's <u>Current Surgical Therapy</u>, 9th ed. (2008)Unknownnoreply@blogger.com107tag:blogger.com,1999:blog-14234389916382717.post-87179121516785600032008-07-16T06:02:00.000-05:002008-07-16T05:46:11.699-05:00Pulmonary Embolism<a href="http://gamma.wustl.edu/vq008vq167.gif"><img style="float:right; margin:0 0 10px 10px;cursor:pointer; cursor:hand;width: 200px;" src="http://gamma.wustl.edu/vq008vq167.gif" border="0" alt="" /></a><br />Here's an essential for management of the postoperative patient...<br /><br /><a><strong>Where does PE originate from?</strong><br /><blockquote>Typically after propogation and embolism of thrombi that develop in deep veins... 79% of patients with PE have evidence of calf DVT.</blockquote></a><br /><p><br /></p><br /><a><strong>What are pathophysiologic sequelae of PE?</strong><br /><blockquote>1. Anatomic obstruction of pulmonary arteries... although pulmonary infarction is typically avoided since lungs are also supplied by bronchial arteries.<br />2. Platelets cause the release of serotonin and vasoactive substances resulting in elevated pulmonary vascular resistance and V/Q mismatch.<br />3. RV afterload increases, leading to RV dilatation, ischemia, and right sided heart failure.</blockquote></a><br /><p><br /></p><br /><a><strong>What are chronic sequelae of DVT and PE?</strong><br /><blockquote>Post-thrombotic syndrome (chronic leg pain/swelling)<br />Chronic thromboembolic pulmonary hypertension</blockquote></a><br /><p><br /></p><br /><a><strong>What are classic risk factors for DVT?</strong><br /><blockquote>Virchow's triad - stasis, injury, and hypercoagulability<br /></blockquote></a><br /><p>Also advanced age, obesity, pregnancy + postpartum period, malignancy, reduced mobility, polycythemia vera, smoking, central venous catheters, HITS, antiphospholipid antibodies, lupus anticoagulant<br />Medications - chemotherapy, oral contraceptives (3X risk), hormone-replacement therapy (2x risk), tamoxifen<br />Acutely-ill, hospitalized, medical patients have a risk of 15%<br /></p><br /><a><strong>What specific populations are at high risk for DVT?</strong><br /><blockquote>Total hip and knee replacement (risk of >50% without prophylaxis)<br />Cancer surgery<br />Major trauma<br />Spinal cord injury</blockquote></a><br /><p><br /></p><br /><a><strong>What are genetic disorders that predispose to risk of venous thromboembolism?</strong><br /><blockquote>Protein C and S deficiency<br />Antithrombin deficiency<br />Factor V Leiden<br />Prothrombin mutation (g20210a)<br />Hyperhomocyteinemia (C677T mutation)<br />Dysfibrinogenemia<br />Plasminogen deficiency<br /></blockquote></a><br /><p><br /></p><br /><a><strong>What isthe most common genetic risk factor for thrombophilia?</strong><br /><blockquote>Factor V Leiden. This causes resistance to activated protein C</blockquote></a><br /><p><br /></p><br /><a><strong>What are signs and symptoms of lower extremity DVT?</strong><br /><blockquote>Leg pain, tenderness, warmth, or swelling</blockquote></a><br />Homan's sign - calf pain with passive dorsiflexion at the ankle<p><br /></p><br /><a><strong>What are signs and symptoms of PE?</strong><br /><blockquote>dyspnea (73%)<br />tachypnea (70%)<br />pleuritic chest pain (66%)<br />rales / crackles (51%)<br />cough (37%)<br />Tachycardia (30%)<br />Leg swelling (28%) or pain (26%)<br />Fourth hearth sound (24%)<br />Loud P2 (23%)<br />Hemoptysis (13%)<br />Palpitations (11%)<br />JVD, systolic murmur, right sided gallop<br />syncope<br />hypotension<br />hypoxemia<br />PEA/cardiac arrest</blockquote></a><br /><p>Cardiogenic shock is diagnosed in 5% of acute PE.<br />While hypoxia and an Aa gradient is common, a normal ABG is seen in up to 20% of PE.<br /></p><br /><a><strong>What are ECG findings of PE?</strong><br /><blockquote>Tachycardia<br />V1-V4 T wave inversion<br />S1-Q3-T3 pattern<br />Right bundle branch block<br />P-wave pulmonale<br />Right axis deviation</blockquote></a><br /><p>These are nonspecific and are more often seen with very large PE<br /></p><br /><a><strong>What are abnormal findings on CXR attributed to PE?</strong><br /><blockquote>Westermark's sign - focal peripheral oligemia caused by PE obstruction<br />Hampton's hump - peripheral wedge seen above diaphragm<br />Palla's sign - enlarged right descending PA</blockquote></a><br /><p><br /></p><br /><a><strong>How does D-dimer testing help with a diagnosis of PE?</strong><br /><blockquote>This is a sensitive (96-98%) but very non-specific test.<br />It must be considered together with clinical suspicion and is better for patients presenting to the emergency room than for general surgical postop patients.<br />If the DDimer is negative in patients with a low-to-moderate pretest probability, imaging is not useful since PE is very unlikely.<br />If the patient has a high pretest probability, don't bother with checking a DDimer and go straight to imaging.</blockquote></a><br /><p><br /></p><br /><a><strong>What imaging strategies are used for diagnosis of PE?</strong><br /><blockquote><br />Spiral CT-angiography (90% sensitivity, 95% specificity)<br />Ventilation/Perfusion Scanning - limitation: frequently non-diagnostic<br />Pulmonary arteriogram<br />Venous duplex for DVT<br />Echocardiography for hemodynamically significant PE</blockquote></a><br /><p><br />Use caution when Cr>1.5 with CTA<br />Avoid V-Q scanning if there is associated cardiopulmonary disease noted on CXR<br /></p><br /><a><strong>What are treatment stategies for DVT?</strong><br /><blockquote>Outpatient management with low-molecular weight heparin transitioning to warfarin with a goal INR of 2-3 for 3-6 months</blockquote></a><br /><p>Pregnant patients can't take warfarin and must be kept on a LMWH... <br /></p><br /><a><strong>What are treatment strategies for PE?</strong><br /><blockquote>PE should be managed by inpatient hospitalization.<br />Parenteral unfractionated heparin (therapeutic PTT), low-molecular weight heparin, or fondaparinux for at least 5 days while starting warfarin - bridging therapeutic INR of 2-3 for 2 consecutive days, continuing treatment for 3-6 months.</blockquote></a><br /><p>Factor VII - measured by the INR - has a half life of 6hrs... however thrombin (factor II) depletion takes 5 days... <br /></p><br /><a><strong>How is unfractionated heparin administered?</strong><br /><blockquote>It is bolused 60-80 U/kg, followed by a continuous infusion of 18 U/kg/hr. The infusion is titrated to a therapeutic PTT (60-80 seconds) by checking the PTT level every 6 hrs.</blockquote></a><br /><p><br /></p><br /><a><strong>What are benefits of LMWH?</strong><br /><blockquote>These have more predictible pharmacokinetics and greater bioavailability than unfractionated heparins, allowing subcutaneous administration once or twice per day.</blockquote></a><br /><p>Therapeutic dosing for enoxaparin is 1mg/kg SC BID or 1.5mg/kg SC QD<br /></p><br /><a><strong>How can you monitor if levels of LMWH are therapeutic?</strong><br /><blockquote>Check anti-factor Xa levels</blockquote></a><br /><p>This is not as convenient as a PTT, but consider this in morbidly obese or pregnant patients, or if there have been issues with renal function.<br /></p><br /><a><strong>What is fondaparinux?</strong><br /><blockquote>A synthetic pentasaccharide that inhibits Factor Xa<br />Structurally, it looks like the antithrombin-binding portion of heparin. It is administered once daily, subcutaneously.</blockquote></a><br /><p>This should not be used in patients with severe renal insufficiency.<br /></p><br /><a><strong>What if the patient has heparin-induced thrombocytopenia with thombosis?</strong><br /><blockquote>The patient should be treated with direct thrombin inhibitors (argatroban or lepirudin). Warfarin treatment should be held until the disease process is controlled and the platelet count has normalized to avoid thrombotic complitcations and warfarin-induced skin necrosis.</blockquote></a><br /><p>Lepirudin is excreted by the kidneys and argatroban is metabolized by liver.<br /></p><br /><a><strong>What is the risk of death from recurrent thromboembolism in patients treated for DVT?</strong><br /><blockquote>0.4%</blockquote></a><br /><p><br /></p><br /><a><strong>What is the risk of death from recurrent thromboembolism in patients treated for PE?</strong><br /><blockquote>1.5%</blockquote></a><br /><p><br /></p><br /><a><strong>What are indications for a vena caval filter?</strong><br /><blockquote>Contraindications to anticoagulation<br />Major bleeding complications during anticoagulation<br />Recurrent DVT or PE while receiving adequate therapy</blockquote></a><br /><p>Retrievable filters can often be inserted... although often times they are forgotten to be removed!<br />The tide is beginning to turn against prophylactically placing IVC filters, but they may be recommended in select trauma patients.<br /></p><br /><a><strong>When is thrombolytic therapy considered for management of PE?</strong><br /><blockquote>If the PE is severe enough to cause cardiogenic shock or right ventricular dysfunction</blockquote></a><br /><p>There is no hard data to answer this question... surgical embolectomy may also be considered in certain cases of massive PE when conservative measures fail.<br /></p><br /><a><strong>What is the overall mortality rate for PE?</strong><br /><blockquote>15% at 3 months</blockquote></a><br /><p><br /></p><br /><a><strong>What is the optimal duration of therapy for a DVT or PE</strong><br /><blockquote>If it is secondary to a reversible risk factor, including the postoperative state, 3-6 months should be sufficient.<br />If it is idiopathic or secondary to a documented hypercoagulable state, 6-12 months can be considered.<br />Patients with a DVT/PE secondary to cancer should be treated until their cancer has resolved, with a LMWH for whe first 3-6 months.<br />Patients with recurrent thromboembolisms may require indefinite therapy.</blockquote></a><br /><p><br /></p><br /><br /><br />Late... SG<br /><br /><u>References</u>:<br />Goldhaber SZ. Pulmonary Embolism. <em>NEJM</em> 339; 1998: 93-104. <br />Tapson VF. Acute Pulmonary Embolism. <em>NEJM</em> 358; 2008: 1037-1052. <br />Cameron's Current Surgical Therapy (9th ed.)Unknownnoreply@blogger.com73tag:blogger.com,1999:blog-14234389916382717.post-79789757049141706682008-07-09T20:55:00.006-05:002008-07-09T22:26:12.391-05:00Acute Calculous Cholecystitis<a href="http://tbn0.google.com/images?q=tbn:tl2ixnjvOR1UaM:http://www.pims.math.ca/science/2003/inverse/gall_bladder.jpeg"><img style="float:right; margin:0 0 10px 10px;cursor:pointer; cursor:hand;width: 200px;" src="http://tbn0.google.com/images?q=tbn:tl2ixnjvOR1UaM:http://www.pims.math.ca/science/2003/inverse/gall_bladder.jpeg" border="0" alt="" /></a><br />A recent edition of <em><a href="http://content.nejm.org/cgi/content/full/358/26/2804">NEJM</a></em> has a nice review on this common surgical topic...<br /><br /><a><strong>What proportion of patients with gallstones become symptomatic?</strong><br /><blockquote>1-4% per year</blockquote></a><br /><br /><a><strong>What proportion of patients with symptomatic cholelithiasis develop cholecystitis?</strong><br /><blockquote>20%</blockquote></a><br /><br /><a><strong>What is gangrenous cholecystitis?</strong><br /><blockquote>When the gallbladder wall undergoes necrosis and gangrene.</blockquote></a><br /><br /><a><strong>What is emphysematous cholecystitis?</strong><br /><blockquote>When gas is visible on imaging in the wall or lumen of the gallbladder... this is indicative of superinfection with gas-forming organisms and may lead to perforation without urgent intervention.</blockquote></a><br /><br /><a><strong>What is Mirizzi's Syndrome?</strong><br /><blockquote>Obstruction of the common bile duct as a result of extrinsic compression of a stone within the gallbladder or cystic duct.</blockquote></a><br /><br /><a><strong>What is Murphy's Sign?</strong><br /><blockquote>Arrest of inspiration while palpating the gallbladder during a deep breath.</blockquote></a><br /><br /><a><strong>What are ultrasonographic findings of acute calculous cholecystitis?</strong><br /><blockquote>Gallstones<br />Gallbladder wall thickening, greater than 5mm<br />Pericholecystic fluid<br />Positive ultrasonographic Murphy's sign<br /></blockquote></a><br /><p>It's also important to assess for choledocholithiasis by evaluating for a common bile duct dilated greater than 7mm or frank CBD stones.</p><br /><p>The PPV of stones + Murphy's sign is 92%.<br />The PPV of stones + GBW thickening is 95%.<br />The NPV of no stones, and a normal GBW and no Murphy's sign is 95%.</p><br /><br /><a><strong>What does a HIDA scan involve?</strong><br /><blockquote>Hepatic scintigraphy uses an IV injection of technetium-labelled iminodiacetic acid analogues. These are excreted by the liver into bile, and allows visualization of the gallbladder within 30 minutes. An absence of filling of the gallbladder after 60 minutes indicates cystic duct obstruction and is 80-90% sensitive for cholecystitis.</blockquote></a><br /><p>Morphine can improve the specificity of the test by increasing resistance at the sphincter of Oddi. Overall, HIDA has greater specificity and accuracy in comparison to ultrasound, but is usually reserved when the diagnosis of cholecystitis is uncertain.</p><br /><br /><a><strong>What is a 'rim sign' on HIDA?</strong><br /><blockquote>A pericholecystic blush that is seen in 30% of patients with acute cholecystitis and 60% of patients with gangrenous cholecystitis.</blockquote></a><br /><br /><a><strong>What are the Tokyo guidelines?</strong><br /><blockquote>Diagnostic criteria for Acute Cholecystitis:<br />Presence of one local sign/symptom, one systemic sign, and any confirmatory finding on an imaging test...<br /><u>Local signs and symptoms</u>: Murphy's sign, RUQ pain or tenderness, RUQ mass<br /><u>Systemic signs</u>: Fever, leukocytosis, elevated CRP</blockquote></a><br /><p>According to the Tokyo guidelines, acute cholecystitis can be subdivided into three grades of severity...</p><br /><br /><a><strong>What are criteria for Grade 1 - Mild Cholecystitis?</strong><br /><blockquote>No organ dysfunction<br />Does not meet criteria for a more severe grade</blockquote></a><br /><p>Early laparoscopic cholecystectomy is recommended.</p><br /><br /><a><strong>What are criteria for Grade 2 - Moderate Cholecystitis?</strong><br /><blockquote>The presence of any of the following:<br />WBC greater than 18,000<br />Palpable, tender RUQ mass<br />Duration greater than 72hrs<br />Marked local inflammation including pericholecystic abscess, hepatic abscess, gangrenous or emphysematous cholecystitis, or biliary peritonitis<br /></blockquote></a><br /><p>Early or delayed laparoscopic cholecystectomy may be considered depending on the scenario and the surgeon's expertise.</p><br /><br /><a><strong>What are criteria for Grade 3 - Severe Cholecystitis?</strong><br /><blockquote>Organ system dysfunction - hypotension requiring pressors, mental status changes, respiratory insufficiency with PaO2/FiO2 less than 300, oliguria, Cr greater than 2.0, INR greater than 1.5, platelet count less than 100k </blockquote></a><br /><p>Management with antibiotics and percutaneous cholecystostomy tube may be considered, reserving surgery for treatment failures.</p><br /><br /><a><strong>What is the optimal timing of cholecystectomy?</strong><br /><blockquote>For most patients, early cholecystectomy may be favored. 15-20% who had their procedures delayed after the initial attack subsided require intervention before their planned lap chole.</blockquote></a><br /><p>In several studies/meta-analyses, there were no differences in operative time or conversion rates between early and delayed lap chole. However, bile duct injuries in general may be more common in the setting of acute cholecystitis. Postoperative bile duct leaks were more common with early intervention (3%) compared to delayed (0%).</p><br /><br /><a><strong>What are the rates of conversion from laparoscopic to open during cholecystectomy for acute cholecystitis?</strong><br /><blockquote>5-30%</blockquote></a><br /><p>These are greater in acute cholecystitis compared to uncomplicated cholelithiasis, but there is no difference between early and delayed intervention.</p><br /><br /><a><strong>When should antibiotics be administered in the setting of cholecystitis?</strong><br /><blockquote>Per the IDSA, a second-generation cephalosporin or a fluoroquinolone and metronidazole shold be administered in the following scenarios: <br />WBC greater than 12,500 or Temperature greater than 38.5C AND<br />Radiographic findings of cholecystitis<br />Also in elderly, diabetics, or immunocompromised<br /></blockquote></a><br /><p>Patients undergoing cholecystectomy will also get a prophylactic perioperative dose, even if they don't require empiric treatment.</p><br /><br /><a><strong>When should percutanous cholecystostomy tubes be used?</strong><br /><blockquote>Patients with Grade 3/Severe cholecystitis<br />Septic shock<br />Poor surgical candidates</blockquote></a><br /><p>Delayed cholecystectomy may be considered at a later time.</p><br /><br />Late... SG<br /><br /><u>References</u>:<br />Strasberg SM. Acute Calculous Cholecystitis. <em>NEJM</em> 2008; 358: 2804-2811.Unknownnoreply@blogger.com10tag:blogger.com,1999:blog-14234389916382717.post-2721933405494408692007-09-16T13:24:00.000-05:002007-09-16T13:25:22.924-05:00Square Knot TutorialIt's been awhile... here's a sweet tutorial on knot tying.<br /><br /><object width="425" height="350"><param name="movie" value="http://www.youtube.com/v/XHk_191uYP4"></param><param name="wmode" value="transparent"></param><embed src="http://www.youtube.com/v/XHk_191uYP4" type="application/x-shockwave-flash" wmode="transparent" width="425" height="350"></embed></object><br /><br />Late... SGUnknownnoreply@blogger.com33tag:blogger.com,1999:blog-14234389916382717.post-1175778530923822152007-05-30T16:37:00.000-05:002008-12-08T21:23:08.699-05:00Rectal Prolapse<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhpYo7h8a3c8U_OWhmlweQpofikA_hGgm8J-8znREkJYGQT5UXdFOAr6GZsnneXw9JwxONOuoeKn4B0owxqr3XaZPtDlTFeFSWxh4wQm-SKK7w8sj6AbiOa2iKd1Qv7IJPMAJBHhV20HQs/s1600-h/Rectum.jpg"><img style="float:right; margin:0 0 10px 10px;cursor:pointer; cursor:hand;" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhpYo7h8a3c8U_OWhmlweQpofikA_hGgm8J-8znREkJYGQT5UXdFOAr6GZsnneXw9JwxONOuoeKn4B0owxqr3XaZPtDlTFeFSWxh4wQm-SKK7w8sj6AbiOa2iKd1Qv7IJPMAJBHhV20HQs/s400/Rectum.jpg" border="0" alt=""id="BLOGGER_PHOTO_ID_5070467652400326018" /></a><br /><a><strong>What is the difference between procidentia and rectal mucosal prolapse?</strong><br /><blockquote>Procidentia is a complete, full-thickness, rectal prolapse.</blockquote></a><br /><a>Procidentia can be differentiated by its circumferential, concentric folding pattern. Mucosal prolapse manifests with deep grooves with a radial pattern.</a><br /><br /><a><strong>What patient population typically presents with rectal prolapse?</strong><br /><blockquote>Older women</blockquote></a><br /><a><strong>What studies may be useful in evaluation of rectal prolapse and disorders in defecation?</strong><br /><blockquote>Colonic transit studies<br />Anorectal manometry<br />Pudendal nerve latency studies<br />Electromyography<br />Cinedefecography</blockquote></a><br /><a><strong>What studies should be performed prior to operative intervention?</strong><br /><blockquote>Colonoscopy or air-contrast barium enema</blockquote></a><br /><a>The colon should be assessed for neoplasms and diverticular disease.</a><br /><br /><a><strong>What are the two primary surgical approaches to manage rectal prolapse?</strong><br /><blockquote>1. Abdominal<br />2. Perineal</blockquote></a><br /><a>The abdominal approaches have lower recurrence rates, while perineal approaches have lower operative morbidity. There are also laparoscopic modifications that can potentially decrease surgical stress on the patient.</a><br /><br /><a><strong>What procedures utilize the abdominal approach?</strong><br /><blockquote>1. Rectopexy (suture or prosthetic)<br />2. Rectopexy with resection of redundant sigmoid</blockquote></a><br /><a><strong>What procedures utilize the perineal approach?</strong><br /><blockquote>1. The Delorme procedure<br />2. The Altemeier procedure<br />3. The Tiersch procedure</blockquote></a><br /><a><strong>What is the Moschowitz repair?</strong><br /><blockquote>Transabdominal reduction of a perineal hernia with closure of the cul-de-sac</blockquote></a><br /><a><strong>What is the Ripstein repair?</strong><br /><blockquote>A transabdominal rectopexy using an anterior mesh sling</blockquote></a><br /><a><strong>What is the Wells repair?</strong><br /><blockquote>A transabdominal rectopexy using a posterior mesh suspension</blockquote></a><br /><a><strong>What is the Delorme procedure?</strong><br /><blockquote>A transperineal mucosectomy</blockquote></a><br /><a>This is commonly performed for mucosal prolapse and is essentially a mucosal sleeve resection with plication of the muscularis.</a><br /><br /><a><strong>What is the Altemeier procedure?</strong><br /><blockquote>A transperineal rectosigmoidectomy</blockquote></a><br /><a>This involves eversion of redundant rectum with a full-thickness resection and anastomosis.</a><br /><br /><a><strong>What is the Tiersch procedure?</strong><br /><blockquote>An anal encirclement procedure that was originally described using a silver wire to encircle the external sphincter within the ischiorectal space, creating an outlet obstruction.</blockquote></a><br /><a>This is considered a palliative procedure, and has been done under local anesthesia using subcutaneously placed polypropylene mesh.</a><br /><br />Late...SG<br /><br /><u>Sources</u>:<br />Schwartz' Principles of Surgery, 8th ed. <br />Mastery of Surgery, 5th ed.Unknownnoreply@blogger.com8tag:blogger.com,1999:blog-14234389916382717.post-38012185213712361522007-04-16T19:06:00.000-05:002008-12-08T21:23:08.884-05:00Electrosurgery<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgtJ6uzTFB57YxwSouFOURpP27yO_jTFuXZfN8GOPj0Sv8B7HmM9b15JCPtgwxE1Dt_PKfxwu3yPzeLSzKitO_gFakkcFtH5AXBvv3gQRNL5XagxSTbH8OcwrmNp-klkyVsozeLuml6cOo/s1600-h/Bovie.jpg"><img style="float:right; margin:0 0 10px 10px;cursor:pointer; cursor:hand;" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgtJ6uzTFB57YxwSouFOURpP27yO_jTFuXZfN8GOPj0Sv8B7HmM9b15JCPtgwxE1Dt_PKfxwu3yPzeLSzKitO_gFakkcFtH5AXBvv3gQRNL5XagxSTbH8OcwrmNp-klkyVsozeLuml6cOo/s200/Bovie.jpg" border="0" alt=""id="BLOGGER_PHOTO_ID_5054228415150941346" /></a><br /><p><strong>Who first demonstrated the principles of electrosurgery?</strong><br /><blockquote>Alex d'Arsonval, a French physicist</blockquote></p><br /><p><strong>Who first produced an electrosurgical unit designed for human use?</strong><br /><blockquote>William Bovie, a Harvard biophysicist</blockquote></p><br /><p><strong>Who popularized the use of "the Bovie"?</strong><br /><blockquote>Harvey Cushing, MD, the father of modern neurosurgery</blockquote></p><br /><p>Cushing is reknown for developing surgical techniques that reduced the mortality rate of brain surgery from 90% to under 10%.</p><br /><p><strong>What is Cushing's Disease?</strong><br /><blockquote>Secondary hypercortisolism, from a pituitary tumor leading to ACTH-hypersecretion.</blockquote></p><br /><p>Cushing's Syndrome is a more general term, referring to any form of symptomatic glucocorticoid excess, whether from an adrenocortical tumor, or exogenous steroids.</p><br /><p><strong>What prestigious award did Cushing receive in his academic career?</strong><br /><blockquote>The Pulitzer Prize, for his biography "A Life of Sir William Osler"</blockquote></p><br /><p><strong>What is Ohm's Law?</strong><br /><blockquote>Voltage = Current * Resistance</blockquote></p><br /><p><strong>What is Impedance?</strong><br /><blockquote>A measure of resistance to flow when using alternating current (AC)</blockquote></p><br /><p>A high cellular water content results in a low tissue impedance.</p><br /><p><strong>What is Alternating Current?</strong><br /><blockquote>Current that cycles in direction at a specific frequency... this comes from a typical US wall outlet at rates of 60Hz.</blockquote></p><br /><p>Electrocautery utilizes direct current (i.e. battery-powered hand-held units), while electrosurgical units utilize alternating current.</p><br /><p><strong>What radiofrequencies cause neuromuscular stimulation?</strong><br /><blockquote>Up to 100kHz</blockquote></p><br /><p><strong>What radiofrequencies cause a generation of heat?</strong><br /><blockquote>200kHz - 5MHz</blockquote></p><br /><p><strong>What is the Joule-Lenz Law?</strong><br /><blockquote>Heat dissipated = (Current-density)squared * Resistance * time</blockquote></p><br /><p>Current-density is current divided by cross-sectional area.<br />Thus, heat generated with electrosurgery is <em>inversely proportional to the area of the electrode</em> and proportional to the time of contact and the impedance of the tissue.</p><br /><p><strong>What is monopolar current?</strong><br /><blockquote>Electricity flowing from a single electrode to the patient.</blockquote></p><br /><p>Monopolar units typically utilize a pencil-type probe that is hand operated. Laparoscopic monopolar cautery may be operated by a foot pedal.</p><br /><p><strong>What is a dispersive electrode?</strong><br /><blockquote>A ground or grounding pad.</blockquote><br /><p><strong>Why is a ground pad placed on the patient when using monopolar cautery?</strong><br /><blockquote>It allows completion of the electric circuit through the patient back to the electrosurgical unit.</blockquote></p><br /><p><strong>Does the size of the ground pad matter?</strong><br /><blockquote>By being large, it disperses current over a greater surface area. If it were small (i.e. detached/poor contact), it could cause generation of enough heat to create a local burn.</blockquote></p><br /><p><strong>What is bipolar current?</strong><br /><blockquote>Electricity flows in a closed circuit between two closely placed electrodes (i.e. bipolar forceps or scissors). Current flow and injury to tissue is limited to the region between the electrodes.</blockquote></p><br /><p>Bipolar units typically allow the use of a lower voltage waveform than monopolar units to acheive hemostasis.</p><br /><p><strong>What are common modes used by monopolar electrosurgical units?</strong><br /><blockquote>1. Cutting<br />2. Coagulation<br />3. Blend</blockquote></p><br /><p><strong>What are the properties of a cutting waveform?</strong><br /><blockquote>It uses a continuous (pure sine-wave), low voltage, high-frequency waveform (500kHz) that concentrates energy on a small area.<br />Instantaneous heating (100 degrees C) results in cellular evaporation at contact, with minimal damage to surrounding tissues.</blockquote></p><br /><p><strong>What are properties of a coagulation waveform?</strong><br /><blockquote>It uses a pulsed, higher-voltage waveform that allows for dispersal of energy deeper into tissue.<br />Heating is less (37- 60 degrees C), causing tissue dessication and protein denaturing, allowing for sealing of blood vessels.</blockquote></p><br /><p><strong>What is fulgaration?</strong><br /><blockquote>Surface coagulation, accomplished by a non-contact method of electrocautery.</blockquote></p><br /><p><strong>What are the properties of a blend mode?</strong><br /><blockquote>This is a combination of cutting and coagulation waveforms. The higher the blend, the higher the coagulation effects.</blockquote></p><br /><p><strong>What happens to tissue impedance during coagulation?</strong><br /><blockquote>As water evaporates and tissue dessicates, the tissue impedance increases, leading to increased coagulative effect.</blockquote></p><br /><p>This can also increase the potential of arcing of the current to a lower impedance tissue, leading to iatrogenic injury.</p><br /><p><em>Remember, current flows in the path of least resistance</em>.</p><br /><p><strong>What are special hazards seen with laparoscopic electrosurgery?</strong><br /><blockquote>1. Insulation failure<br />2. Direct coupling<br />3. Capacitor coupling</blockquote></p><br /><p>Injury can occur to non-target tissue out of view of the surgical team!</p><br /><p><strong>What is insulation failure?</strong><br /><blockquote>When a defect in the covering of the active electrode allows current to contact non-target tissue.</blockquote></p><br /><p><strong>What is direct coupling?</strong><br /><blockquote>When the tip of the active electrode comes into contact with another metal instrument in the surgical field.</blockquote></p><br /><p><strong>What is capacitor coupling?</strong><br /><blockquote>When stray current from an electrode develops by a storage of charge. This can be minimized by activating the active electrode only when it is in contact with target tissues and limiting the amount of time on the coagulation setting.</blockquote></p><br /><p>This can sometimes occur with devices that contain both plastic and metal, allowing for insulation of charge by the instrument or trocar.</p><br /><br />For a resource that has some pretty decent illustrations, consider this online <a href="http://www.valleylab.com/education/poes/index.html">course</a> at Valleylab.<br /><br />Late... SG<br /><br /><u>Sources</u>:<br />O'Leary's Physiologic Basis of Surgery, 3rd ed.<br />Jones CM, Pierre KB, Nicoud IB, Stain SC, Melvin WV. Electrosurgery. <em>Curr Surg</em> 2006; 63: 458-463.Unknownnoreply@blogger.com12tag:blogger.com,1999:blog-14234389916382717.post-4558340133724467562007-04-09T21:19:00.000-05:002007-04-10T12:13:36.308-05:00Aphorisms and Quotations<a href="http://images.barnesandnoble.com/images/8870000/8879056.jpg"><img style="float:right; margin:0 0 10px 10px;cursor:pointer; cursor:hand;width: 200px;" src="http://images.barnesandnoble.com/images/8870000/8879056.jpg" border="0" alt="" /></a><br /><p><strong>Here's a <a href="http://search.barnesandnoble.com/booksearch/isbnInquiry.asp?z=y&EAN=9781903378113&itm=2">book</a> for any quote enthusiast:</strong><br /><blockquote><u>Aphorisms & Quotations for the Surgeon</u>. Edited by Moshe Schein. tfm Publishing, Ltd. : Shrewsbury, UK; 2003.</blockquote></p><br /><p>For those of you who have been looking for a convenient resource to pepper your next powerpoint presentation with a breath of surgical history, this is the book for you. Even better if you are looking for a little inspiration at the end of the day. In addition to instilling the text with witticisms of his own, Moshe Schein has organized the numerous quotes into 94 different subject headings, ranging from the ubiquitous organ systems, to topics such as academics, dogma, greatness, love, money, politics, gimmicks, fame, ethics, empathy, and errors.</p><br /><p>Here are a few:</p><br /><blockquote>There are 4 degrees of intra-operative hemorrhage: <br />1. "Why did I get involved in this operation?" <br />2. "Why did I become a surgeon?" <br />3. "Why did I study to become a doctor?" <br />4. "Why was I born?"<br />-Alexander A Artemiev</blockquote><br /><br /><blockquote>When I am carrying out a big, unusual, or difficult operation, I never plan anything later that day.<br />-Francis D. Moore</blockquote><br /><br /><blockquote>It is a most gratifying sign of the rapid progress of our time that our best textbooks become antiquated so quickly.<br />-Theodor Billroth</blockquote><br /><br /><blockquote>I would like to see the day when somebody would be appointed surgeon somewhere who had no hands, for the operative part is the least part of the work.<br />-Harvey W. Cushing</blockquote><br /><br /><blockquote>Medical examinations: they are no tests of the man. They are only tests for his memory for facts. They tell us nothing of his judgement, tact, energy, enthusiasm, idealism, reason, observation, temperament, disposition, honesty, loyalty, courage, truthfulness, or intelligence. Memory of facts means little. The other things mean nearly all.<br />-J. Chalmers Da Costa</blockquote><br /><br /><blockquote>The pleasure of a physician is little, the gratitude of patients is rare, and even rarer is material reward, but these things will never deter the student who feels the call within him.<br />-Theodor Billroth</blockquote><br /><br /><blockquote>You must always be students, learning and unlearning till your life's end, and if, gentlemen, you are not prepared to follow your profession in this spirit, I implore you to leave its ranks and betake yourself to some third-class trade.<br />-Joseph Lister</blockquote><br /><br />Late... SGUnknownnoreply@blogger.com4tag:blogger.com,1999:blog-14234389916382717.post-150528115235926572007-04-07T20:46:00.000-05:002007-04-18T15:57:38.121-05:00Pancreatic Transplantation<a href="http://www.pbs.org/wgbh/aso/databank/entries/images/b4bant01m1844.jpeg"><img style="float:right; margin:0 0 10px 10px;cursor:pointer; cursor:hand;width: 100px;" src="http://www.pbs.org/wgbh/aso/databank/entries/images/b4bant01m1844.jpeg" border="0" alt="" /></a><br /><p><strong>Who discovered insulin?</strong><br /><blockquote>Banting and Best (1921)</blockquote></p><br /><p>Sir Frederick Banting of the University of Toronto was awarded the Nobel Prize for Medicine/Physiology along with John MacCleod in 1923. He initially refused to accept the award until his research assistant Charles Best's work was acknowledged, but ultimately ended up sharing his portion of the award with Best.</p><br /><p><strong>What are the secondary complications of diabetes mellitus?</strong><br /><blockquote>Retinopathy<br />Nephropathy<br />Neuropathy<br />Enteropathy<br />Vasculopathy</blockquote></p><br /><p>Diabetes is the leading cause of kidney failure, blindness, nontraumatic amputation, and impotence.</p><br /><p>Exogenous insulin can prevent the acute metabolic complications and decrease the secondary complications of diabetes, but cannot maintain a homeostatic environment.</p><br /><p><strong>What is the benefit of pancreatic transplantation?</strong><br /><blockquote>It can establish normoglycemia and insulin independence and can halt the progression of secondary complications of diabetes</blockquote></p><br /><p><strong>What is the drawback of pancreatic transplantation?</strong><br /><blockquote>Immunosuppression</blockquote></p><br /><p><strong>What are the methods of pancreatic transplantation?</strong><br /><blockquote>1. PAK - pancreas after kidney transplantation<br />2. SPK - simultaneous pancreatic/kidney transplantation<br />3. PTA - pancreas transplant alone</blockquote></p><br /><p>Often PAK and SPK is performed because immunosuppression is already required for a kidney transplant. <br />PTA may be performed for nonuremic diabetics with a poor quality of life from ketoacidosis, labile glycemic control, or progression of secondary complications of diabetes.</p><br /><p><strong>When was the first pancreatic transplant performed?</strong><br /><blockquote>1966 as an SPK. This was three years after the first kidney transplant.</blockquote></p><br /><p><strong>What techniques are used in the drainage of the pancreas?</strong><br /><blockquote>1. Enteric drainage (requires creatinine monitoring, for PAK or SPK)<br />2. Bladder drainage (requires monitoring of urine amylase)</blockquote></p><br /><p>Enteric drainage was performed in the 1970's but was superceded by ureteral, then bladder drainage. Bladder drainage became common in the 1980's, but in the 1990's enteric drainage became repopularized. Enteric drainage has been thought to be more physiologic, but requires a kidney transplant to monitor for rejection.</p><br /><p><strong>What are elements of the preoperative evaluation for pancreatic transplantation?</strong><br /><blockquote>1. Assessment of degree of kidney dysfunction<br />2. Evaluation of secondary complications of diabetes<br />3. Coronary Angiography<br />4. Evaluation of peripheral arterial disease and iliac vessel patency<br />5. Rule out Malignancy<br />6. Rule out Infection</blockquote></p><br /><p><strong>Why is coronary angiography often routinely performed?</strong><br /><blockquote>Because severe diabetics are at risk for coronary arterial disease without angina.</blockquote></p><br /><p><strong>What are the options based on kidney function?</strong><br /><blockquote>1. PTA if Cr<2.0mg/dL with minimal proteinuria<br />2. PAK or SPK with moderate kidney insufficiency</blockquote></p><br /><p><strong>What are the donor possibilities for kidney/pancreas transplants?</strong><br /><blockquote>1. Deceased-donor SPK<br />2. Living-donor kidney transplant followed by deceased-donor PAK<br />3. SPLK: Simultaneous deceased-donor pancreas and living-donor kidney transplant<br />4. Living-donor SPK</blockquote></p><br /><p><strong>What are the elements of preparation of the pancreas graft?</strong><br /><blockquote>1. Removal of the spleen and excess duodenum<br />2. Ligation of the vessels at the root of the mesentery.<br />3. Reconstruction of the arterial system of the graft (Y-graft)</blockquote></p><br /><p><strong>What is a pancreatic Y-graft reconstruction?</strong><br /><blockquote>The donor SMA and splenic artery are connected using a reversed segment of donor iliac artery.</blockquote></p><br /><p>This creates a common arterial inflow channel for the pancreatic graft</p><br /><p><strong>What is the outflow of the pancreatic graft?</strong><br /><blockquote>Portal vein</blockquote></p><br /><p><strong>What are the components of the pancreatic transplant?</strong><br /><blockquote>1. Heterotopic placement of pancreatic graft (right iliac fossa or mid-abdomen)<br />2. Arterial anastomosis: Y-graft to common iliac artery or distal aorta<br />3. Venous anastomosis: donor portal vein to recipient iliac vein (systemic) or recipient SMV (portal)<br />4. Drainage procedure: duodenocystostomy or duodenoenterostomy (i.e. Roux en Y)</blockquote></p><br /><p><strong>What are complications associated with bladder drainage?</strong><br /><blockquote>Dehydration, chronic refractory metabolic acidosis, recurrent UTI, hematuria, bladder calculi, urethritis, urinary leaks</blockquote></p><br /><p>10-20% with bladder drainage are converted to enteric drainage secondary to complications</p><br /><p><strong>When is bladder drainage commonly used?</strong><br /><blockquote>With PTA (allows for rejection monitoring via urinary amylase levels), or when the kidney and pancreas are from different donors.</blockquote></p><br /><p><strong>What are signs of rejection after pancreatic transplants?</strong><br /><blockquote>-increased creatinine (kidney/pancreas transplants)<br />-decreased urinary amylase (bladder drainage)<br />-increased serum amylase<br />-increased serum glucose</blockquote></p><br /><p><strong>What are other complications of pancreatic transplantation?</strong><br /><blockquote>1. Infections (10%)<br />2. Thrombosis (6%)<br />3. Hemorrhage (<1% of graft loss)<br />4. Pancreatitis<br />5. Urologic complications (see bladder drainage)</blockquote></p><br /><strong>What are the reported graft survival rates after pancreatic transplantation?</strong><br /><blockquote>SPK - 90% at 1yr<br />PAK - 85% at 1yr<br />PTA - 75% at 1yr</blockquote></p><br /><p><strong>What is a pancreatic islet cell transplant?</strong><br /><blockquote>Cells are extracted from the islets of Langerhans of donor pancreas and injected into a diabetic patient's portal vein.</blockquote></p><br /><p>This potentially avoids a major surgical procedure, but the patient will still need long-term immunosuppression (use is still often limited to patients needing kidney transplants).</p><br /><p><strong>What are problems with Islet cell transplantation?</strong><br /><blockquote>Islet cell rejection is difficult to monitor and diagnose<br />Complications such as hepatic abscesses, bacteremia, and portal hypertension can occur<br />Poor results (<5% insulin-independence at 1yr)</blockquote></p><br /><br />Late... SG<br /><br /><u>Source</u>:<br />Schwartz' Principles of Surgery, 8th ed.Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-14234389916382717.post-76317393758655075672007-04-06T20:37:00.000-05:002007-04-09T20:10:10.077-05:00Breast MRILast week's edition of <em>NEJM</em> had a report on the ability of MRI to detect clinically occult breast cancers in the contralateral breast of patients diagnosed with breast cancer. The link can be accessed <a href="http://content.nejm.org/cgi/content/abstract/356/13/1295">here</a>...<br /><br />This multi-institutional study assessed patients with unilateral breast cancers with a normal mammogram performed in the the contralateral breast. 1007 patients were enrolled at 25 sites; 987 patients were eligible, and 969 participatated with the study. Among index lesions, 58% had infiltrating ductal carcinoma, 20% had DCIS, and 10% had lobular carcinoma.<br /><br />After evaluation of the contralateral breast using MRI, 33/969 women were diagnosed with breast tumors within the following year; 30 of these lesions were identified by MRI.<br /><br />Overall, the sensitivity of breast MRI in this population was 91% (CI 76-98%), the specificity was 88% (CI 86-90%), the negative predictive value was 99% (CI 99-100%), and the positive predictive value was 21% (14-27%). The specificity and PPV were significanly higher for postmenopausal women than premenopausal or perimenopausal women.<br /><br />Positive MRIs resulted in recommendation for biopsy in 135 women; biopsies were performed in 121/969 women (12%). Among the 30 cancers detected, 40% were DCIS and 60% were infiltrating ductal carcinomas (94% T1, 6% T2).<br /><br />So overall, there was a 3% rate of detection of occult cancers, and a negative biopsy rate of 9%. 25% of biopsies were cancers... It is uncertain how this data would translate to survival benefit.<br /><br />However, because of this and other reports, <strong>the American Cancer Society has provided new recommendations for the use of screening MRI in high risk populations</strong>. Here's the open access <a href="http://caonline.amcancersoc.org/cgi/reprint/57/2/75">pdf</a>!<br /><br />Here, MRI would be recommended as an <u>adjunct to screening mammography</u>. It also shouldn't be performed unless the facility has the capacity to perform MRI-guided biopsies.<br /><br /><p><strong>In what populations does the ACS recommend Screening Breast MRI based on evidence?</strong><br /><blockquote>BRCA mutation<br />First-degree relative (untested) of BRCA positive patient.<br />Life-time risk calculation >20-25%</blockquote></p><br /><p><strong>In what populations does the ACS recommend Screening Breast MRI based on expert / consensus opinion?</strong><br /><blockquote>Radiation to the chest between ages 10-30<br />Li-Fraumeni Syndrome and 1st degree relatives<br />Cowden Syndrome and 1st degree relatives<br />Bannayan-Riley-Ruvalcaba Syndrome and 1st degree relatives</blockquote></p><br /><p><strong>What is Li-Fraumeni Syndrome?</strong><br /><blockquote>An autosomal dominant disease caused by p53 mutation, resulting in predisposition to sarcomas, breast cancers, brain tumors, adrenocortical tumors, as well as numerous others (gastric, pancreatic, ovarian, melanomas, lymphomas...)</blockquote></p><br /><p><strong>What is Cowden Syndrome?</strong><br /><blockquote>An autosomal dominant disease caused by PTEN mutation, resulting in multiple hamartomatous neoplasms.</blockquote></p><br /><p><strong>What is Bannayan-Riley-Ruvalcaba Syndrome?</strong><br /><blockquote>Another disease caused by PTEN mutation, resulting in neonatal overgrowth, macrocephaly, lipomas, hemangiomas, lymphangiomas, and hamartomatous polyposis.</blockquote></p><br /><p><strong>In what populations does the ACS not recommend screening Breast MRI?</strong><br /><blockquote>Women at less than 15% lifetime risk of breast cancer.</blockquote></p><br /><br />They recommended the <a href="http://astor.som.jhmi.edu/BayesMendel/brcapro.html">BRCAPRO</a> and <a href="http://www.palmgear.com/index.cfm?fuseaction=software.showsoftware&prodID=29820">Claus</a> models for calculating the risk, which should be based primarily on family history and genetics for breast and ovarian cancer syndromes. The Gail model was not recommended for determining risk for MRI purposes because it doesn't take account an early age of onset of family members, or 2nd degree relatives with breast cancer.<br /><br /><br />Late... SG<br /><br /><u>Sources</u>:<br />Lehman CD, Gatsonis C, Kuhl CK, Hendrick RE, Pisano ED, Hanna L, Peacock S, Smazal SF, Maki DD, Julian TB, DePeri ER, Bluemke DA, and Schnall MD for the ACRIN Trial 6667 Investigators Group. MRI Evaluation of the Contralateral Breast in Women with Recently Diagnosed Breast Cancer. <em>NEJM</em> 2007; 356(13): 1295-1303.<br /><a href="http://content.nejm.org/cgi/content/full/356/13/1362">Smith RA. The Evolving Role of MRI in the Detection and Evaluation of Breast Cancer. <em>NEJM</em> 2007; 356(13): 1362-1364.</a><br />Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, and Russell CA for the American Cancer Society Breast Cancer Advisory Group. American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography. <em>CA Cancer J Clin</em> 2007; 57: 75-89.Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-14234389916382717.post-50111936158869225752007-04-03T22:22:00.000-05:002008-12-08T21:23:09.088-05:00Clinical Trials<p><strong>What is a Phase I Clinical Trial?</strong><br /><blockquote>An experimental study that is designed to evaluate the safety of a treatment.</blockquote></p><br /><p>For pharmacotherapeutics, this often is a trial that escalates a drug to determine dose-limiting toxicities.</p><br /><p><strong>What is a Phase II Clinical Trial?</strong><br /><blockquote>An experimental study that evaluates the biologic response of a treatment.</blockquote></p><br /><p>The results of this kind of trial are often compared to historical controls.</p><br /><p><strong>How are responses often categorized for cancer therapeutics?</strong><br /><blockquote>CR - Complete Response<br />PR - Partial Response<br />SD - Stable Disease<br />PD - Progressive Disease</blockquote></p><br /><p><strong>What is a Phase III Clinical Trial?</strong><br /><blockquote>An experimental study that evaluates the efficacy of a treatment.</blockquote></p><br /><p>This is typically a randomized, controlled trial.</p><br /><p><strong>What is blinding?</strong><br /><blockquote>A method to minimize bias from the investigators and/or the participants where the individuals are not made aware of treatment assignments.</blockquote></p><br /><p><strong>What are eligibility criteria?</strong><br /><blockquote>These may be inclusion or exclusion criteria that specify the type of patients that can or cannot be enrolled in the study.</blockquote></p><br /><p>Studies typically exclude minors and pregnant women for ethical reasons.<br />Studies may also limit participation to people without certain medical problems (i.e., coagulopathy, renal insufficiency).<br />Studies may try to include only certain patients (i.e. Blunt Trauma patients with a GCS less than 8)</p><br /><p><strong>What are some clinical endpoints commonly studied in oncology Phase III trials?</strong><br /><blockquote>Overall survival<br />Disease-free survival</blockquote></p><br /><p>Distant disease-free survival may describe the proportion of patients who were alive and did not develop metastatic disease, while disease-free survival describes patients who were alive and did not develop any recurrence (locoregional/distant).</p><br /><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgnfTbCbY1HHEhYzm-HQuTKoTFrX1gbZ2ajcvxETJ3m4sv374pg1vfXbXaiamXYiF0JQgFYHtCTUz6SZab5ecmtkRSDyz6ulVy-fEzmWt1UL5zGjMwTYKZMh6_q3sSd3ScZeM7xGZBKX08/s1600-h/KaplanMeierSurvivalCurves.JPG"><img style="float:right; margin:0 0 10px 10px;cursor:pointer; cursor:hand;" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgnfTbCbY1HHEhYzm-HQuTKoTFrX1gbZ2ajcvxETJ3m4sv374pg1vfXbXaiamXYiF0JQgFYHtCTUz6SZab5ecmtkRSDyz6ulVy-fEzmWt1UL5zGjMwTYKZMh6_q3sSd3ScZeM7xGZBKX08/s200/KaplanMeierSurvivalCurves.JPG" border="0" alt=""id="BLOGGER_PHOTO_ID_5049461522318977170" /></a><p><strong>What are methods typically used for survival analysis?</strong><br /><blockquote>1. Kaplan-Meier Analysis<br />2. Cox Proportional Hazard Models</blockquote></p><br /><p>Kaplan-Meier curves provide estimates of survival based on the length of follow-up for each individual patient. Patients who are lost to follow-up are <u>censored</u>, while patients who do not survive will cause the curve to go down in proportion to the total number of patients followed at that time interval.</p><br /><p>A Cox Proportional Hazard Model is a form of multivariate analysis that allows the investigator to control for known variables (i.e. age, gender,..) that might influence an outcome.</p><br /><p><strong>What is the Intention-to-Treat Principle?</strong><br /><blockquote>The investigators analyze the data keeping patients in their original treatment assignment groups, regardless if patients crossed-over to the other treatment group.</blockquote></p><br /><p>If you designed a study that randomized patients to stenting versus surgical revascularization, and some patients in the stent group ended up having surgery, their outcomes would still be analyzed in the stent group. By not following the intention-to-treat principle, the outcomes of the stent group may be biased against stent failures.</p><br /><p><strong>What is clinical equipoise?</strong><br /><blockquote>The balance between evidence of an experimental therapeutic's efficacy and the degree of uncertainty surrounding the evidence.</blockquote></p><br /><p>This allows for an ethical deliberation leading an investigator to decide to start a study, or to stop a study early.</p><br /><p><strong>What is an interim analysis?</strong><br /><blockquote>A planned preliminary assessment of data to allow for monitoring of various outcome measures.</blockquote></p> <br /><p>Stopping rules may terminate a trial early if the data show harm to patients.</p><br /><p><strong>What is the Hawthorne effect?</strong><br /><blockquote>The concept that the knowledge of being observed will affect the behavior of the participants.</blockquote></p><br /><p>While this was initially described in reference to studies on worker productivity under different lighting conditions, patients may avoid unhealthy behaviors if they know they are participating in a clinical trial.</p><br /><p><strong>What is a Phase IV Clinical Trial?</strong><br /><blockquote>After FDA approval of a therapeutic, this is a study that evaluates its effectiveness in a wider population, as well as follows for late adverse events.</blockquote></p><br /><p><strong>So to recap the types of clinical trials:</strong><br /><blockquote>I - Safety<br />II - Response<br />III - Efficacy (RCT)<br />IV - Effectiveness</blockquote><br /><br />Late... SG<br /><br /><u>Source</u>:<br />Essentials of Surgical Oncology, Mosby (2007).Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-14234389916382717.post-9469814521798791472007-04-01T17:10:00.000-05:002007-04-04T01:41:12.706-05:00Trust in Defecation<object width="425" height="350"><param name="movie" value="http://www.youtube.com/v/jsVgi8hoFFc"></param><param name="wmode" value="transparent"></param><embed src="http://www.youtube.com/v/jsVgi8hoFFc" type="application/x-shockwave-flash" wmode="transparent" width="425" height="350"></embed></object><br /><br />April Fools... SGUnknownnoreply@blogger.com0tag:blogger.com,1999:blog-14234389916382717.post-80765681704755942782007-03-31T21:38:00.000-05:002007-04-04T09:19:30.737-05:00Cost Aware Care<a href="http://mutualfunds.about.com/cs/humor/l/blclipartgal.htm"><img style="FLOAT: right; MARGIN: 0px 0px 10px 10px; WIDTH: 104px; CURSOR: hand; HEIGHT: 116px" height="333" alt="" src="http://z.about.com/d/mutualfunds/1/0/S/3/money4.jpg" border="0" /></a><em>Archives of Surgery</em> recently published a study from investigators at UConn and Yale examining the use of a cost card to educate their residents on the costs of various services.<br /><br />Here's a <a href="http://archsurg.ama-assn.org/cgi/content-nw/full/142/3/222/SOA60027T3">link</a> to their cost card for services.<br /><br />The <a href="http://archsurg.ama-assn.org/cgi/reprint/142/3/222">pdf</a> is open access.<br /><br />Enjoy! SG<br /><br /><u>Source</u>:<br />Chandawarkar RY, Taylor S, Abrams P, Duffy A, Voytovich A, Longo WE, Kozol RA. Cost-Aware Care: Critical Core Competency. <em>Arch Surg</em> 2007; 142: 222-226.Unknownnoreply@blogger.com3tag:blogger.com,1999:blog-14234389916382717.post-24308081035194948222007-03-25T22:31:00.000-05:002007-03-26T10:54:54.530-05:00McVay Herniorrhaphy<a href="http://upload.wikimedia.org/wikipedia/en/thumb/8/87/Astley_Cooper.jpeg/180px-Astley_Cooper.jpeg"><img style="float:right; margin:0 0 10px 10px;cursor:pointer; cursor:hand;width: 200px;" src="http://upload.wikimedia.org/wikipedia/en/thumb/8/87/Astley_Cooper.jpeg/180px-Astley_Cooper.jpeg" border="0" alt="" /></a><br /><p>Today we'll talk about the Cooper's Ligament Repair... a nice one to know for femoral hernias and situations where you need to avoid mesh prostheses...</p><br /><strong>Who was Sir Astley Cooper (1768-1841)?</strong><br /><blockquote>At the wee age of 16 years old, as a budding surgical apprentice, he developed a groin hernia of his very own, which was managed by a truss. In 1804, he published his works on the Anatomy and Surgical Treatment of Hernia.</blockquote></p><br /><p><strong>What are some of his eponymous anatomical structures?</strong><br /><blockquote>1. Superior pubic / pectineal ligament<br />2. Suspensory ligaments of the breast<br />3. Fascial covering of the spermatic cord</blockquote></p><br /><p><strong>What are the borders of Fruchaud's myopectineal orifice?</strong><br /><blockquote>medial - rectus abdominus muscle<br />lateral - iliopsoas muscle<br />superior - internal oblique and transverse abdominus<br />inferior - Cooper's ligament and pubis</blockquote></p><br /><p>The inguinal ligament spans and divides the myopectineal orifice, running from the anterior superior iliac spine to the pubic tubercle. The spermatic cord crosses above and the iliac vessels cross below.</p><br /><p>The <a href="http://hernia.tripod.com/mpo">myopectineal orifice</a> is significant as it is a region of aponeurotic fibers that can attenuate, resulting in a groin hernia.</p><br /><p><strong>What types of hernias occur in the myopectineal orifice?</strong><br /><blockquote>1. Direct Inguinal - through transversalis fascia (medial to inferior epigastric) <br />2. Indirect Inguinal - through inguinal ring (lateral to inferior epigastric)<br />3. Femoral - through femoral ring</blockquote></p><br /><p>All three types can be addressed using a Cooper's ligament repair...</p><br /><p><strong>What are the borders of the inner ring of the femoral canal?</strong><br /><blockquote>lateral - femoral vein<br />anteromedial - iliopubic tract<br />posterior - Cooper's ligament</blockquote></p><br /><p><strong>Who were the first surgeons to utilize Cooper's ligament in herniorrhaphy?</strong><br /><blockquote>1. Giuseppe Ruggi (1892) - sutured inguinal ligament to Cooper's ligament<br />2. Georg Lotheissen (1897) - sutured the conjoint tendon to Cooper's ligament<br />3. Chester McVay (1942)</blockquote></p><br /><p>Chester McVay noted in his doctoral thesis that the normal insertion of the transverse abdominus and the transversalis fascia was on Cooper's ligament, and not the inguinal ligament. His technique for herniorraphy focused on reconstruction of these anatomical relationships.</p><br /><p><strong>What are key elements of the McVay Herniorrhaphy?</strong><br /><blockquote>1. Suturing the transversalis arch to Cooper's ligament, from the pubic tubercle to the femoral vein.<br />2. Transition sutures to avoid the femoral vein and close the femoral canal, then suturing the transversalis arch laterally to the iliopubic tract. <br />3. Making a generous relaxing incision to decrease tension to the repair.</blockquote></p><br /><p><strong>Give me details!</strong><br /><blockquote>1. Begin with an inguinal approach, incising the skin and soft tissues after adequate local anesthesia. <br />2. Open the external oblique aponeurosis to the external ring.<br />3. Attempt to preserve the ilioinguinal nerve.<br />4. Mobilize the spermatic cord. Isolate it with a penrose.<br />5. Open the internal ring, incising the posterior wall of the inguinal canal towards the pubic tubercle (through the internal oblique aponeurosis and the transversalis fascia.)<br />6. Retract the spermatic cord superiorly and identify Cooper's ligament. Palpate for the femoral vessels.<br />7. Define the space between the femoral vein and the pubic tubercle from lateral to medial, with conversion of any femoral hernia sac into an inguinal one.<br />8. Hernia sacs can be opened to inspect for intraabdominal pathology if strangulation is suspected. Resection may be necessary, otherwise contents can be reduced.<br />9. Indirect hernia sacs can be isolated from the spermatic cord and transected at the level of the internal ring. Direct hernia sacs can be inverted in the repair. <br />10. Mobilize the transversus abdominus arch superiorly. Any attenuated transversalis fascia and internal oblique can be excised.<br />11. Place relaxing incision superior to pubic tubercle at the point of fusion of the external oblique aponeurosis and the anterior rectus sheath. This should extend superiorly for about 4-5 inches.<br />12. Place patient in Trendelenberg position to minimize intraabdominal injury.<br />13. The preperitoneal tissues can be carefully imbricated to keep them out of the repair if necessary.<br />14. Place interupted sutures (10) between the transverse abdominus arch and Cooper's ligament, beginning at the pubic tubercle towards the medial edge of the femoral vein. Place a clamp around the sutures to tie later.<br />15. Begin placing transition sutures (3) between the transverse abdominus arch, Cooper's ligament, and the iliopubic tract. The medial two of these sutures will be placed so they overlap in between the prior lateral sutures.<br />16. Continue placing interrupted sutures between the transversus abdominus arch and the iliopubic tract, creating a neo-internal ring.<br />17. Tie all the sutures from medial to lateral. <br />18. Return the cord to its natural position.<br />19. Close the external ring over the cord using a continuous 2-0 Vicryl, creating a neo-external ring.<br />20. Close skin according to preference.</blockquote></p><br /><p>Here's a <a href="http://www.medscape.com/pi/editorial/clinupdates/2000/357/art-gilbert-fig15.jpeg">picture</a>, just before placement of the transition stitches!</p><br />Late... SG<br /><br /><u>Sources</u>:<br />Nyhus and Condon's Hernia, 5th ed. (2002)<br />Hachisuka T. Femoral hernia repair. <em>Surg Clin N Am</em> 2003; 83: 1189-1205.Unknownnoreply@blogger.com172tag:blogger.com,1999:blog-14234389916382717.post-64429229371461129732007-03-23T17:07:00.000-05:002007-04-02T21:59:17.586-05:00Intermittent Claudication<a href="http://tbn0.google.com/images?q=tbn:G9sEMzlk3Uz4wM:http://www.tulsaworld.com/health/images/cp-legs2.jpg"><img style="FLOAT: right; MARGIN: 0px 0px 10px 10px; WIDTH: 93px; CURSOR: hand; HEIGHT: 124px" height="127" alt="" src="http://tbn0.google.com/images?q=tbn:G9sEMzlk3Uz4wM:http://www.tulsaworld.com/health/images/cp-legs2.jpg" border="0" /></a><br /><p>This week's edition of <a href="http://www.nejm.org"><em>NEJM</em></a> has a sweet little review on Intermittent Claudication. Nice opportunity to discuss this progressively painful topic...</p><br /><p><strong>What are risk factors for peripheral artery disease?</strong><br /><blockquote>Cigarette smoking<br />Diabetes mellitus<br />Hypertension<br />Hyperlipidemia<br />Hyperhomocysteinemia<br />Age greater than 50y<br />Male gender</blockquote></p><br /><p>Remember that peripheral vascular disease and coronary artery disease go hand in hand.</p><br /><p><strong>How do patients with intermittent claudication typically present?</strong><br /><blockquote>leg muscle discomfort on exertion, relieved by rest<br />leg fatigue<br />difficulty walking</blockquote></p><br /><p>Pain may be in the calves, thighs, feet, and/or buttocks. It is helpful to document the number of blocks the patient can walk before symptoms arise.</p><br /><p><strong>What does <em>claudico</em> (L) mean?</strong><br /><blockquote>To limp</blockquote></p><br /><p><strong>What are findings commonly seen on physical exam?</strong><br /><blockquote>abnormal pulses<br />vascular bruits<br />low ankle-brachial index</blockquote></p><br /><p><strong>What is the ankle-brachial index (ABI)?</strong><br /><blockquote>The ratio of systolic blood pressure taken in the arm over the systolic blood pressure taken at the ankle. This indicates severity of lower extremity peripheral vascular disease. Can be taken at rest and after exercise.<br />>0.9 Normal<br />0.7-0.9 Mild obstruction<br />0.4-0.7 Moderate obstruction<br /><0.4 Severe obstruction - critical ischemia</blockquote></p><br /><p><strong>What are issues with ABI measurements in diabetics?</strong><br /><blockquote>Diabetics have non-compressible vessels from medial calcification so ABI measurements may not be valid indicators of peripheral vascular disease. An alternative is measuring toe-brachial indices using photoplethysmography.</blockquote></p><br /><p><strong>What is the natural history of intermittent claudication?</strong><br /><blockquote>The risk of limb loss is low for patients without diabetes (<2%).<br />The risk of limb loss increases 3X with diabetics requiring drug therapy. <br />The risk of limb loss increases 20-25% for every 0.1 reduction in ABI.<br />The risk of cardiovascular events (MI, CVA) is about 5-7%/year.</blockquote></p><br /><p>Peripheral vascular disease is a continuum from intermittent claudication, to rest pain, to gangrene with tissue loss. Only 20-30% of patients with intermittent claudication progress to require some kind of intervention.</p><br /><p><strong>What is pseudoclaudication?</strong><br /><blockquote>Leg pain from non-vascular causes (i.e., osteoarthritis, spinal stenosis, compartment syndrome, sciatica)</blockquote></p><br /><p><strong>What are adjunctive non-invasive studies for further working-up peripheral artery disease?</strong><br /><blockquote>Doppler probe survey<br />Duplex ultrasound<br />Segmental pressure recordings<br />Pulse-volume recordings</blockquote></p><br /><p>These may help assess the location, presence, and severity of a lesion.</p><br /><p><strong>What is a Doppler probe survey?</strong><br /><blockquote>Using a hand-held continuous-wave Doppler probe unit, the femoral, popliteal, posterior tibial, and dorsalis pedis arterial signals are assessed. With severe stenosis or occlusion the Doppler pulse becomes monophasic and low-pitched.</blockquote></p><br /><p><strong>What is a triphasic arterial signal?</strong><br /><blockquote>1) High-pitched sound, representing forward systolic blood flow.<br />2) Low-pitched sound from reversed flow in early diastole<br />3) Medium-pitched sound, from resumed forward flow.</blockquote></p><br /><p><strong>How does duplex ultrasound evaluate stenoses?</strong><br /><blockquote>The doppler component allows measurement of blood flow velocity.<br />20-49% stenosis = increase of peak systolic velocity of 30-100% across lesion.<br />Critical (>50%) stenosis = increase in peak systolic velocity by greater than 100%<br />Total occlusion = no flow</blockquote></p><br /><p>Duplex has a 82% sensitivity and 92% specificity in detecting stenoses.</p><br /><p><strong>Why is a reduction of only half of the luminal diameter considered a "critical" stenosis?</strong> <br /><blockquote>Reduction in half the diameter represents a 75% reduction in the cross-sectional area of the vessel, leading to a 94% reduction in flow. Critical stenosis is when this reduction in cross-sectional area compromises blood flow leading to symptoms.</blockquote></p><br /><p><strong>What are determinants of Resistance to flow?</strong><br /><blockquote>By rearranging Poiseuille's Law, R = (8*viscosity*L)/(pi*r^4)<br />This means that a longer stenosis will increase vascular resistance linearly.<br />This also means that decreasing the vessel lumen radius will increase the resistance to the fourth power!</blockquote></p><br /><p><strong>What is a pulse volume recording?</strong><br /><blockquote>A segmental plethysmograph that records arterial pressure contours at various cuffs placed on an extremity. This allows for an indirect assessment of blood flow across the extremity. The distinct upstroke (anacrotic slope), pulse peak, downstroke (catacrotic slope), and wavelengths inform the interpreter, with flattening of the contour seen with severe stenosis.</blockquote></p><br /><p><strong>What are segmental leg pressures?</strong><br /><blockquote>Simply measuring thigh, calf, and ankle systolic pressures for assessment of extremity occlusion. All pressures are taken with reference to the dorsalis pedis doppler signal.</blockquote></p><br /><p><strong>What is the gold-standard for evaluation of peripheral artery disease?</strong><br /><blockquote>Angiography<br />Used if a surgical or endovascular intervention is planned. Alternatives to consider include MRA and CTA.</blockquote></p><br /><p><strong>What are complications of angiography?</strong><br /><blockquote>Contrast reactions (<4%)<br />Contrast nephropathy (<2%)<br />Bleeding (<2%)<br />Cholesterol embolization (<0.1%)</blockquote></p><br /><a href="http://tell.fll.purdue.edu/JapanProj/FLClipart/Verbs/read.gif"><img style="float:right; margin:0 0 10px 10px;cursor:pointer; cursor:hand;width: 200px;" src="http://tell.fll.purdue.edu/JapanProj/FLClipart/Verbs/read.gif" border="0" alt="" /></a><br /><p><strong>How do you treat peripheral vascular disease presenting as intermittent claudication?</strong><br /><blockquote>You READ before you even think about operating!<br />1. Risk-factor modification<br />2. Exercise<br />3. Antiplatelet Therapy<br />4. Drugs</blockquote></p><br /><p><strong>What are methods of risk-factor modification?</strong><br /><blockquote>smoking cessation<br />regular exercise<br />dietary modification<br />control of hyperlipidemia (LDL <100, or <70 if high risk)<br />control of diabetes (HgA1c <7%)<br />control of blood pressure (<140/<90 or <130/<80 with DM)</blockquote></p><br /><p><strong>What are the benefits of Exercise?</strong><br /><blockquote>There is Level 1 evidence that exercise increases maximum walking distance by 150% over 3-12 months, with improvements greater than angioplasty and antiplatelet therapy (<a href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD000990/frame.html">Cochrane Review</a>).</blockquote></p><br /><p>The greatest benefit has been seen from continued walking until pain is maximal, at least 3 times per week, for at least 30min, for more than 6 months. Give the leg a chance to collateralize!</p><br /><p><strong>What are forms of antiplatelet therapy?</strong><br /><blockquote>1. Aspirin - reduces cardiovascular death by 25%<br />2. Clopidogrel (Plavix) - use as an alternative to aspirin<br />3. Cilostazol (Pletal) - increases walking distance by 50% after 3-6mo</blockquote></p><br /><p>There is Class I, Level A evidence of benefit from cilostazol (Pletal) in patients with intermittent claudication. <br />There is Class IIb evidence (conflicting) of benefit from pentoxifylline (Trental).</p><br /><p><strong>What is the <a href="http://www.ahrq.gov/clinic/uspstf/uspsasmi.htm">USPSTF recommendation</a> for Aspirin use?</strong><br /><blockquote>All patients at increased risk of coronary artery disease should consider aspirin chemoprevention. (Grade A)</blockquote></p><br /><p><strong>How does Aspirin work?</strong><br /><blockquote>It irreversible acetylates the enzyme cyclooxygenase. By blocking thromboxane A2 formation in platelets it decreases platelet aggregation and local vasoconstriction. Low-dose aspirin is thought to inhibit platelet thromboxane more than endothelial prostacyclin. Higher dose aspirins likely inhibit both.</blockquote></p><br /><p><strong>What does thromboxane A2 do to blood vessels?</strong><br /><blockquote>Causes vasoconstriction</blockquote></p><br /><p><strong>What does prostacyclin (PGI2) do to blood vessels?</strong><br /><blockquote>Causes vasodilation</blockquote></p><br /><p><strong>How does clopidogrel (Plavix) work?</strong><br /><blockquote>It blocks the ADP receptor on platelets, inhibiting platelet activation and the coupled activation of the glycoprotein IIb/IIIa complex (fibrinogen receptor). <br />This leads to inhibition of platelet aggregation and white clot (platelet/fibrinogen plug) formation. </blockquote></p><br /><p><strong>How does cilostazol (Pletal) work?</strong><br /><blockquote>It is a reversible PDE (phosphodiesterase) inhibitor that increases platelet cAMP, leading to vasodilatation and inhibition of platelet aggregation.</blockquote></p><br /><p><strong>What is the mechanism of action of pentoxifylline (Trental)?</strong><br /><blockquote>It is thought to improve the rheologic properties of blood by lowering blood viscosity and improving erythrocyte flexibility.</blockquote></p><br /><p><strong>What are other drugs to consider?</strong><br /><blockquote>Statins (HMG CoA Inhibitors)<br />Beta blockers<br />ACE Inhibitors<br />Nicotine replacement therapies</blockquote></p><br /><p><strong>What is the most common vascular lesion associated with intermittent claudication?</strong><br /><blockquote>Superficial femoral artery stenosis or occlusion</blockquote></p><br /><p>The region where the distal SFA enters Hunter's adductor canal is especially at risk.</p><br /><p><strong>What are indications for revascularization by angioplasty or surgery?</strong><br /><blockquote>Claudication that limits lifestyle or ability to perform job<br />Claudication that is refractory to exercise and pharmacologic therapy<br />Claudication that progresses to rest pain</blockquote></p><br /><p><strong>What are favorable lesion features for percutaneous transluminal angioplasty (PTA)?</strong><br /><blockquote>Single stenosis less than 10cm long<br />Single occlusion less than 5cm long</blockquote></p><br /><p><strong>What type of lesions is surgery preferred?</strong><br /><blockquote>Occlusion greater than 20cm<br />Occlusion of the popliteal or tibial-peroneal vessels.</blockquote></p><br /><p>Surgery is also strongly considered for multiple lesions over 15cm and recurrent lesions after two endovascular interventions.</p><br /><p><strong>What are outcomes of femoropopliteal PTA?</strong><br /><blockquote>Patency rates of 87% at 1y, 69% at 3y, and 55% at 5y.</blockquote></p><br />We'll talk about surgical approaches to infrainguinal occlusive disease at a later time... SG<br /><br /><u>Sources</u>:<br /><a href="http://content.nejm.org/cgi/content/short/356/12/1241">White C. Intermittent Claudication. <em>NEJM</em> 2007; 356: 1241-1250.</a><br />Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. <em>Cochrane Database of Systematic Reviews</em> 2000; 2:CD000990.<br />Handbook of Patient Care in Vascular Diseases, 4th ed. Lippincott (2001).<strong></strong>Unknownnoreply@blogger.com21tag:blogger.com,1999:blog-14234389916382717.post-10337452138653127252007-03-22T15:17:00.000-05:002008-12-08T21:23:09.350-05:00Ultrasonography<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi0GNm1qjXGEZrA9RfAv-HAMWyCppB-lE0YRp9cE3LWCc5vMguFDuFAd9M26DvWdvGSllKx2N9JHcKY7-lzly3B26vnRnxgv7GUGnylipDAkm72JZMWSmmrVXU9ytbf0h3BgmCNSrNZbBY/s1600-h/ultrasound.jpg"><img style="float:right; margin:0 0 10px 10px;cursor:pointer; cursor:hand;" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi0GNm1qjXGEZrA9RfAv-HAMWyCppB-lE0YRp9cE3LWCc5vMguFDuFAd9M26DvWdvGSllKx2N9JHcKY7-lzly3B26vnRnxgv7GUGnylipDAkm72JZMWSmmrVXU9ytbf0h3BgmCNSrNZbBY/s200/ultrasound.jpg" border="0" alt=""id="BLOGGER_PHOTO_ID_5044853316481540370" /></a><br /><blockquote><em>Ultrasound is to the Surgeon as the Stethoscope is to the Internist!</em></blockquote><br /><p>Various technologies assist us in our ability to diagnose and create new therapeutic interventions. Today we'll talk about diagnostic ultrasound.</p><br /><p><strong>What are advantages of ultrasound compared to other imaging modalities?</strong><br /><blockquote>Portable<br />Inexpensive<br />Quick<br />Dynamic - Spatially and Temporally<br />Easily Repeatable<br />Minimizes Risk to Patient </blockquote></p><br /><p><strong>What are the disadvantages of ultrasound?</strong><br /><blockquote>Learning curve<br />Operator dependence<br />Inability to assess through bowel gas or in obese patients<br />Inability to assess through bone or calcifications</blockquote></p><br /><p><strong>What is the piezoelectric effect?</strong><br /><blockquote>The process of converting electric energy into mechanical/acoustical energy, and vice versa. An ultrasonic transducer contains PZT (lead zirconate titanate) crystals that have piezoelectric properties allowing for signal conversion of a mechanical stress into a voltage.</blockquote></p><br /><p><strong>What is the pulse-echo principle?</strong><br /><blockquote>When a transmitted ultrasound wave (pulse) approaches tissue, part of the signal is reflected and part of the signal is transmitted into tissue. Waves that are reflected back (returning echoes) generate a signal that is interpreted by the transducer.</blockquote></p><br /><p><strong>What is amplitude?</strong><br /><blockquote>The height of a wave. This decreases (attenuates) as waves travel through tissue or are scattered.</blockquote></p><br /><p><strong>What is frequency?</strong><br /><blockquote>The amount of wave cycles per second. This is inversely proportional to wavelength.</blockquote></p><br /><p>Diagnostic ultrasound commonly uses frequencies of 2-20MHz. <br />The upper limit of detection by the human ear is 20kHz.</p><br /><p><strong>What is the "Frequency Trade-Off"?</strong><br /><blockquote>Using high frequency transducers, there is greater spatial resolution.<br />Using low frequency transducers, there is less signal attenuation.</blockquote></p><br /><p>Because of this, abdominal transducers are generally low frequency (i.e. 3.5MHz curvilinear transducer), with greater depth visualization. A better transducer to visualize a superficial structure like a thyroid nodule might be a 10MHz linear probe.</p><br /><p><strong>What is the difference between linear-array and curvilinear-array transducers?</strong><br /><blockquote>Linear transducers provide more near-field (superficial) information.<br />Curvilinear transducers have a sector-like field of view that becomes wider with increasing depth.</blockquote></p><br /><p><strong>What is Acoustic Impedance?</strong><br /><blockquote>A property of the tissue of interest related to its density and the speed of sound through it. Tissues with different acoustic impedance will be distinguishable using ultrasound (i.e. gallstone versus gallbladder). Sound waves reflect at the interface of different acoustic impedances.</blockquote></p><br /><p><strong>Why do you use a coupling gel on the transducer probe at the interface with the patient's skin?</strong><br /><blockquote>It removes air from the interface and matches the acoustic impedance of the crystal with the contact surface.</blockquote></p><br /><p><strong>What is A-mode ultrasound?</strong><br /><blockquote>Amplitude Modulation<br />This is the most basic, one-dimensional form of ultrasound, which records the amplitude of the echo in respect to time. It is now obsolete.</blockquote></p><br /><p><strong>What is B-mode ultrasound?</strong><br /><blockquote>Brightness Modulation<br />This is the most commonly used form of ultrasound, converting amplitude into pixel brightness/intensity. The more wave reflection, the greater echo amplitude, the greater the brightness or signal echogenicity.</blockquote></p><br /><p><strong>What is echogenicity?</strong><br /><blockquote>Characterizes the appearance of tissues based on relative brightness (echo amplitude).<br />Isoechoic = similar brightness<br />Hyperechoic = brighter/whiter<br />Hypoechoic = darker<br />Anechoic = black</blockquote></p><br /><p><strong>What is M-mode ultrasound?</strong><br /><blockquote>Movement Modulation<br />This allows assessment of a moving structure like heart valves, and was used prior to the development of 2D-real time B-mode displays.</blockquote></p><br /><p><strong>How does 2D-real time B-mode ultrasound work?</strong><br /><blockquote>The transducer contains an array of piezoelectric crystals, or contains a moving crystal. Sequential pulses of ultrasound beams are swept in a plane to create a field of echoes that is reconstructed as a 2D-image.</blockquote></p><br /><p><strong>What is Tissue Harmonic Imaging?</strong><br /><blockquote>An enhanced form of 2D-real time imaging using a complex form of signal processing that rejects artifacts from scatter.</blockquote></p><br /><p><strong>What is Spatial Compound Imaging?</strong><br /><blockquote>Another enhanced form of 2D-real time imaging that reduces speckle and graininess by averaging multiple signals.</blockquote><br /><p><strong>What is the Doppler Effect?</strong><br /><blockquote>A change in the received frequency of an observer due to a difference in relative motion between the source and observer. As a consequence, if the source is moving toward an observer it is received with a shift to a higher frequency. If the source is moving away it is received with a shift to a lower frequency. This is helpful to assess blood flow velocity.</blockquote></p><br /><p><strong>What is a Duplex ultrasound?</strong><br /><blockquote>Combines 2D real-time B-mode ultrasound imaging with color Doppler ultrasound. This allows you to simultaneously visualize the structure of blood vessels or heart valves and see a color correlate of flow velocity through them. </blockquote></p><br /><p><strong>Does red flow mean it is an artery?</strong><br /><blockquote>No! The red and blue colors with Duplex imaging are arbitrary and refer to positive or negative directionality of flow with reference to the transducer.</blockquote><br /><p><strong>What are the basic components of an ultrasound machine?</strong><br /><blockquote>Monitor<br />Keyboard<br />Signal-Processing Unit<br />Transducer<br />Image Recorder</blockquote></p><br /><p><strong>What is Time Gain Compensation?</strong><br /><blockquote>A form of signal processing that compensates for attenuation due to increasing level of depth.</blockquote></p><br /><p><strong>What is the FAST exam?</strong><br /><blockquote>Focused Abdominal Sonogram for Trauma<br />It is a rapid survey for assessment for truncal injuries as part of the secondary survey of trauma patients. It can be used to detect hemoperitoneum as an alternative to performance of diagnostic peritoneal lavage in hemodynamically unstable patients. It also surveys for pericardial blood. This may be repeated as necessary.</blockquote></p><br /><p><strong>What are components of the FAST exam?</strong><br /><blockquote>Using a 3.5MHz curvilinear-array transducer, and ensuring the patient has a full bladder, the following views can be imaged, assessing the heart and the three most dependent regions in the body:<br />1. Subxiphoid View (r/o pericardial effusion)<br />2. RUQ View (r/o blood in Morrison's Pouch, hepatorenal recess)<br />3. LUQ View (r/o blood in the splenorenal recess)<br />4. Pelvic View</blockquote></p><br /><p><strong>Why do you image the heart first?</strong><br /><blockquote>It allows a standard to set the gain for detection of blood.</blockquote></p><br /><p><strong>What are common forms of ultrasound use in acute care and ICU settings?</strong> <br /><blockquote>-Localization of vessels for central venous access<br />-Screening for deep venous thrombosis<br />-Detection of pleural effusions and performance of thoracentesis<br />-Diagnosis of acute sinusitis<br />-Detection of foreign bodies in soft tissue<br />-Evaluation of patients with abdominal pain (i.e. cholelithiasis)<br />-Identification of abdominal aortic aneurysms<br />-Confirmation of reduction of incarcerated hernias<br />-Evaluation for fascial defect from suspected wound dehiscence<br />-Detection of abscesses<br />-Echocardiography</blockquote></p><br /><p><strong>What does Echocardiography assess?</strong><br /><blockquote>Cardiac Anatomy<br />Heart wall function<br />Heart valvular function<br />Ejection Fraction</blockquote></p><br /><p><strong>What advantages does Transesophageal Echo (TEE) have over Transthoracic Echo (TTE)?</strong><br /><blockquote>TEE has the transducer in the esophagus, which is closer to the heart, and avoids artifact from the ribs and lungs.<br />It has improved imaging of the valves and aorta.</blockquote></p><br /><p><strong>What are the US Preventive Services Task Force Recommendations for Screening for Abdominal Aortic Aneurysms?</strong><br /><blockquote>-Grade B: One-Time screening for AAA using ultrasound in men 65-75y who have smoked.<br />-Grade C: No recommendation for men 65-75y who have never smoked.<br />-Grade D: Against routine screening for AAA in women. </blockquote></p><br /><p><strong>What are indications for breast ultrasound?</strong><br /><blockquote>-Assessment of palpable or vaguely palpable breast mass<br />-Assessment of lesion detected on mammogram<br />-Evaluation of nipple discharge with assessment of ducts<br />-Assessment of dense breast<br />-Assessment of pregnant or lactating patients<br />-Follow-up of seromas, hematomas, prostheses<br />-Assessment of abscesses<br />-Guide intervention - FNA, Core-needle biopsy, or excisional biopsy</blockquote></p><br /><p><strong>What probe is commonly used for breast ultrasound?</strong><br /><blockquote>7.5MHz linear-array transducer</blockquote></p><br /><p><strong>What are lesion characteristics to assess with breast ultrasound?</strong><br /><blockquote>1. Margins<br />2. Retrotumoral acoustic phenomenon: shadowing, enhancement<br />3. Echogenicity<br />4. Compression effect on shape and internal echoes</blockquote></p><br /><p><strong>What does a simple cyst look like on ultrasound?</strong><br /><blockquote>Sharp, smooth-margined round mass<br />Homogeneous, anechoic interior<br />Some compression<br />Posterior enhancement</blockquote></p><br /><p><strong>What are features of malignant breast lesions on ultrasound?</strong><br /><blockquote>Indistinct, jagged margins<br />Few internal echoes<br />Posterior shadowing<br />Taller than wide</blockquote></p><br /><p><strong>What are common uses of intraoperative ultrasound (IOUS)?</strong><br /><blockquote>Hepatobiliary and pancreatic procedures<br />-detection of stones<br />-detection of mass lesions<br />-detection of vessels and ducts<br />-diagnosing splenic or portal vein thrombosis<br />-guide biopsy and ablative procedures</blockquote></p><br /><p>IOUS can be done with conventional or laparoscopic transducers.</p><br /><p><strong>What type of transducers are commonly used for endoscopic ultrasound?</strong><br /><blockquote>7-20MHz radial or sector-scanning transducers</blockquote></p><br /><p>Radial transducers provide for a 360-degree visual field<br />Sector-scanning systems can be easier to perform Doppler and biopsy capabilities.</p><br /><p><strong>What type of transducer is used for endorectal ultrasound?</strong><br /><blockquote>A 7-10MHz radial transducer covered by a water-filled latex balloon.</blockquote></p><br /><p><strong>For TNM staging of a rectal cancer by endorectal ultrasound, what prefix is used?</strong><br /><blockquote>uTNM = as assessed by EUS<br />cTNM = as assessed clinically<br />pTNM = as assessed by pathologist <br />yTNM = if neoadjuvant chemotherapy was used<br />mTNM = if multiple primaries were found at a single site<br />rTNM = for a tumor recurrence<br />aTNM = if detected at autopsy</blockquote></p><br /><br />Late... SG<br /><br /><u>Sources</u>:<br />O'Leary's Physiologic Basis of Surgery, 3rd ed.<br />Hangiandreou NJ. AAPM/RSNA Physics Tutorial for Residents: Topics in US. B-Mode US: Basic Concepts and New Technology. <em>RadioGraphics</em> 2003; 23: 1019-1033.<br />Rozycki GS. Surgeon-Performed Ultrasound: Its Use in Clinical Practice. <em>Ann Surg</em> 1998; 228: 16-28.<br /><a href="http://www.ahrq.gov/clinic/uspstf/uspsaneu.htm">US Preventive Services Task Force</a> AAA Screening Recommendations (2005)Unknownnoreply@blogger.com1tag:blogger.com,1999:blog-14234389916382717.post-38055404070198780472007-03-19T10:14:00.000-05:002008-12-08T21:23:09.494-05:00Society of Surgical Oncology, 2007<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiEq0pCnxEeabhDya_g7jjbsR948kmTwO65_heeXfuzZy5hb5WKEMzcxv3nCbdeXDCKch1bPpT8fBpDC88LNjs_h9KE788Zqh2xQcrm8gE5OchiyA1JYldHu4JAqHkEsyWJ5CpLQAdQedU/s1600-h/SSO+DC.jpg"><img style="float:right; margin:0 0 10px 10px;cursor:pointer; cursor:hand;" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiEq0pCnxEeabhDya_g7jjbsR948kmTwO65_heeXfuzZy5hb5WKEMzcxv3nCbdeXDCKch1bPpT8fBpDC88LNjs_h9KE788Zqh2xQcrm8gE5OchiyA1JYldHu4JAqHkEsyWJ5CpLQAdQedU/s200/SSO+DC.jpg" border="0" alt=""id="BLOGGER_PHOTO_ID_5048964654164273218" /></a><br />Just got back from a surprisingly cold meeting in one of my favorite towns, Washington, DC. While I was hoping to see a cherry blossom or two, it was obviously a few weeks too early, so I settled for the shelter of a dark conference hall.<br /><br />A few highlights:<br /><br />-SSO President, Raphael Pollock, announced an interest in opening SSO membership to all surgeons, rather than its primarily academic base of membership.<br />-Efforts have been initiated to make Surgical Oncology a board-certified specialty.<br /><br />-Great talks overall on hepatobiliary surgery<br />-Eddie Abdalla (MD Anderson) gave a nice overview of portal vein embolization... Before this talk, I never really realized the rationale between PVE over hepatic artery embolization. From a physiological standpoint, PVE creates portal flow diversion that increases GI trophic factors that lead to hypertrophy of the contralateral liver lobe. Neat!<br />-Alan Koffron (Northwestern) had a cine-filled presentation on Laparoscopic Hepatic Resection. Here the technology seemed key, with use of a mix of the <a href="http://www.ritamedical.com/products/habibLap.shtml">Laparoscopic Habib</a> (RF bipolar; RITA Medical Systems), Saline-Enhanced Radiofrequency Ablation (SERF), and staplers.<br /><br />-The Basic Science lecture by Leroy Hood was interesting, stressing the importance of viewing biology as an informational science - a product of digital and analog systems and signals (very engineering based concepts!)<br /><br />-Among GI presentations, the peripheral opioid antagonist, methylnaltrexone, had been randomized in 65 patients with segmental colectomies receiving IV PCA narcotics. Methylnaltrexone led to significant improvements in 1st bowel movement (1 day) and discharge eligibility (1 day), but didn't effect time to PO tolerance, flatus, or actual discharge. The study seemed underpowered to detect differences in those factors.<br /><br />-Amongst the Breast talks, extirpation of the primary in Stage IV breast cancer was revisited by a retrospective review of the SEER database by investigators at Wash U. Nearly half of the 9734 patients with Stage IV breast cancer had surgical excision of the breast tumor, with a survival advantage of about 35% after controlling for age, race, tumor size/grade, ER/PR status, and use of radiotherapy.<br /><br />-Amongst the exhibitors, Incisive Surgical has developed a new skin stapler that creates an everted, interrupted subcuticular closure using absorbable polylactide-polyglicolide (<a href="http://www.insorb.com">INSORB</a>). The device contains 20 absorbable staples and is packaged with disposable forceps. The closure can then be reinforced with adhesive strips.<br /><br />-In conferences, my favorite talks are always the debates.<br />-The first was regarding excision alone versus excision+radiotherapy for DCIS, between Mel Silverstein and Terry Mamounas. I was surprised to learn that based on SEER data, a third of all DCIS in this country is being treated with excision alone. Mamounas discussed the differences in local recurrence seen in a few RCTs, including NSABP B-17, and the use of prospective rather than retrospective data. Silverstein focused on pathologic criteria (i.e. Van Nuys -margin, grade, necrosis) and age as important determinants of recurrence, and that margin status was not an issue of focus in the RCTs. He also stressed the fact that there is no survival benefit from radiation in DCIS, and that you would have to irradiate 250 people to save 1 life... a low absolute versus relative benefit. Plus there are issues with access, and later use of radiation in the same breast.<br />-The third debate was regarding local excision versus LAR/APR for Stage I cancer, between Julio Garcia-Aguilar and James Fleshman. Clearly the limitation of local excision is an inability to assess nodal status. Garcia-Aguilar focused on staging with EUS and MRI and proper preoperative selection, as well as avoiding the morbidities associated with abdominal approaches, including sexual and urinary function, as well as stoma formation. Fleshman saw as a limitation access to tumors (although this may be obviated with Transanal Endoscopic Microsurgery), as well as the high rates of local recurrence seen with local excision, especially for T2 tumors. I only wished they discussed more about the role of neoadjuvant therapies in their discussion.<br />-I think the consensus from the discussions of both DCIS and Stage 1 rectal cancer is that <em>ideally</em> with good preoperative selection criteria "doing less" may be appropriate in a subset of favorable patients (i.e. excision alone for DCIS with low VNPI score; local excision for small, low-grade uT1N0 rectal cancers without lymphovascular invasion), but the safer approach would continue to be "doing more" (excision + XRT; APR/LAR), primarily due to issues related to local recurrence. The problems are the decisions for favorable criteria depend on the quality of the pathologist, radiologist, and/or the EUS-operator and are probably highly variable between institutions.<br /><br />But does one treatment fit all? It made me think about how new assays like Oncotype DX can help select for patients who can benefit from chemotherapy in addition to Tamoxifen with node-negative ER+ breast cancer. Rather than treating all patients aggressively with chemo, now only the subset of patients at high risk of recurrence need to be treated.<br /><br />What if there were objective molecular marker(s) for severity of rectal cancer that could help select patients who might be amenable to local excision? What if there were biomarkers of invasion that could classify DCIS into low risk and high risk categories? DCIS is technically a pre-invasive stage of cancer, but what if we could know through a marker whether it confers risk of recurrence or harbors invasion without worrying about the ability of the human eye to detect it?<br /><br />Late... SGUnknownnoreply@blogger.com5tag:blogger.com,1999:blog-14234389916382717.post-19753685367186635422007-03-09T20:31:00.000-05:002007-03-28T12:41:16.071-05:00Mr. Gumby Needs a Brain Specialist...<object height="350" width="425"><param name="movie" value="http://www.youtube.com/v/tqyxXX3Ra4A"><param name="wmode" value="transparent"><embed src="http://www.youtube.com/v/tqyxXX3Ra4A" type="application/x-shockwave-flash" wmode="transparent" width="425" height="350"></embed></object><br /><br /><object height="350" width="425"><param name="movie" value="http://www.youtube.com/v/cEkT5uspE3c"><param name="wmode" value="transparent"><embed src="http://www.youtube.com/v/cEkT5uspE3c" type="application/x-shockwave-flash" wmode="transparent" width="425" height="350"></embed></object><br /><br />My Brain Hurts! SGUnknownnoreply@blogger.com1tag:blogger.com,1999:blog-14234389916382717.post-59125397579101317322007-03-08T22:30:00.000-05:002008-12-08T21:23:09.691-05:00Parenteral Nutrition<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiGikh5b9UaOdBTTTu5gxOISU6SKdj_i-Rg-d7-TPqdim_eEhIpKp-foVmGDMYkxdk_w6E85ETpukEGteBjzIZVYwRGOg0tL6N-ele_UcPevyFJ-_GDDJORZvfmcVUd0H3obNuQk_-_DOM/s1600-h/TPN.jpg"><img style="float:right; margin:0 0 10px 10px;cursor:pointer; cursor:hand;" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiGikh5b9UaOdBTTTu5gxOISU6SKdj_i-Rg-d7-TPqdim_eEhIpKp-foVmGDMYkxdk_w6E85ETpukEGteBjzIZVYwRGOg0tL6N-ele_UcPevyFJ-_GDDJORZvfmcVUd0H3obNuQk_-_DOM/s320/TPN.jpg" border="0" alt=""id="BLOGGER_PHOTO_ID_5048961724996577314" /></a><br /><p><strong>What are indications for parenteral nutrition?</strong><br /><blockquote>-Inability to feed enterally<br />-Inability to maintain nutritional goals enterally<br />-Newborns with GI anomalies<br />-Short bowel syndrome<br />-Malabsorption syndromes<br />-High-output enterocutaneous fistulas (>500ml/day)<br />-Enteroenteric, enterocolic, enterovesical fistulas<br />-Postoperative ileus over 7-10days<br />-Hypermetabolic critically-ill patients<br />-Functional GI disorders (i.e. post-CVA)<br />-Malnutrition/cachexia from malignancy</blockquote></p><br /><p><strong>What are lengths of intact remaining small bowel from massive resection that usually necessitate chronic TPN?</strong><br /><blockquote>Less than 100cm without colon or ileocecal valve<br />Less than 50cm with the colon and an intact ileocecal valve</blockquote></p><br /><p><strong>What are contraindications to hyperalimentation?</strong><br /><blockquote>-Enteral nutrition is possible<br />-Good nutritional status<br />-Hemodynamic instability<br />-Severe metabolic derangements (i.e. hyperglycemia, hyperosmolarity, electrolytes)</blockquote></p><br /><p><strong>What is PPN?</strong><br /><blockquote>Peripheral parenteral nutrition<br />Administered through a peripheral catheter<br />Often used for short term, sometimes while waiting for central venous access<br />Dextrose: 5-10% (D5 or D10)<br />Protein: 3%</blockquote></p><br /><p><strong>What is TPN?</strong><br /><blockquote>Total parenteral nutrition<br />Requires central venous access due to high osmolarity<br />Dextrose: 15-25%<br />Crystalline amino acids: 3-5%<br />With or without Lipids: 10-15% of calories, limited to 1 g/kg/d</blockquote></p><br /><p><strong>What are classic signs of fatty acid deficiency?</strong><br /><blockquote>Dry, Scaly Dermatitis<br />Alopecia</blockquote></p><br /><p><strong>What are recommended caloric requirements?</strong><br /><blockquote>Normal to Mild Stress 25-30 kcal/kg/day<br />Moderate stress 30 kcal/kg/day<br />Severe stress 30-35 kcal/kg/day</blockquote></p><br /><p><strong>What are recommended protein requirements?</strong><br /><blockquote>Normal 1.0 g/kg/day<br />Mild stress 1.2 g/kg/day<br />Moderate stress 1.5 g/kg/day<br />Severe stress 2.0 g/kg/day</blockquote></p><br /><p><strong>What are calorie equivalents for carbohydrate, protein, and lipid?</strong><br /><blockquote>carbohydrate = 4 kcal/g<br />IV dextrose = 3.4 kcal/g<br />protein = 4 kcal/g<br />lipid = 9 kcal/g</blockquote></p><br /><p><strong>What are common supplements and additives for TPN infusions?</strong><br /><blockquote>Multivitamins<br />Vitamin K (not in multivitamin preparations)<br />Trace minerals (Zn, Cu, Mn, Cr, Se)<br />Insulin<br />Heparin<br />H2 Blockers</blockquote></p><br /><p><strong>What are signs of Zinc deficiency?</strong><br /><blockquote>Excematoid Dermatitis (intertriginous zones)<br />Impaired wound healing</blockquote><br /><p><strong>What is a sign of Copper deficiency?</strong><br /><blockquote>Microcytic anemia</blockquote></p><br /><p><strong>What is a sign of Chromium deficiency?</strong><br /><blockquote>Impaired glucose tolerance</blockquote></p><br /><p><strong>What does Selenium deficiency cause?</strong><br /><blockquote>Cardiomyopathy</blockquote></p><br /><p><strong>What are recommendations for electrolytes in TPN?</strong><br /><blockquote>Sodium 60-150 mEq/d<br />Potassium 70-150 mEq/d<br />Phosphorus 20-30 mmol/d<br />Magnesium 15-20 mEq/d<br />Calcium 10-20 mmol/d</blockquote></p><br /><p><strong>What is the role of administering chloride or acetate salts in TPN?</strong><br /><blockquote>Maintenance of acid-base status<br />Maintenance of electrolyte balance<br />Sodium and potassium can be administered in either form</blockquote></p><br /><p><strong>What are issues with administering too much calcium and phosphorus in TPN?</strong><br /><blockquote>They can precipitate in solution</blockquote></p><br /><p><strong>Can glutamine be administered in TPN?</strong><br /><blockquote>It is typically unstable in solution<br />Glutamine dipeptide is available in Europe and can be given parenterally.</blockquote></p><br /><p><strong>What are considerations when starting TPN?</strong><br /><blockquote>1. Electrolyte status<br />2. Volume status<br />3. Acid-Base status<br />4. Risk for Septic complications</blockquote></p><br /><p><strong>What is often monitored when administering TPN?</strong><br /><blockquote>Daily weights<br />Electrolytes, starting daily then every 2-3days when stable<br />CBC, BUN, LFTs, Phos, Mg at least weekly<br />Glucose every 6 hours</blockquote></p><br /><p><strong>What are methods of short-term central venous access for TPN?</strong><br /><blockquote>16G percutaneous catheters via subclavian vein or internal jugular vein</blockquote></p><br /><p><strong>What are methods of long-term central venous access?</strong><br /><blockquote>PICC line (via basilic or cephalic vein)<br />Port-a-Caths<br />Tunneled catheters (Hickman, Broviac, Groshong)<br />Hohn catheters</blockquote></p><br /><p><strong>Where should the catheter tip be placed?</strong><br /><blockquote>In the superior vena cava adjacent to the right atrium</blockquote></p><br /><p><strong>What are catheter-related complications?</strong><br /><blockquote>Cardiac arrhythmias<br />Septicemia<br />Pneumothorax<br />Hemothorax<br />Subclavian artery injury<br />Thoracic duct injury<br />Air embolism<br />Catheter or guidewire embolism<br />Cardiac perforation</blockquote></p><br /><p><strong>What are metabolic complications of TPN?</strong><br /><blockquote>1. Hyperglycemia - administer insulin and correct electrolytes<br />2. Overfeeding - can cause ventilator dependence and hepatic steatosis<br />3. Cholestasis - monitor transaminases, alkaline phosphatase, and bilirubin</blockquote></p><br /><p><strong>What is the risk of catheter-related infection?</strong><br /><blockquote>For catheters present over 7 days, infection risks of 5-10% have been reported.<br />Among catheter tips that reach microbiology labs, only 15-25% are culture positive.<br />Catheter-related septicemia carries mortality rates of 12-25%.</blockquote></p><br /><p><strong>What clinical findings would make you suspicious of catheter-related infection?</strong><br /><blockquote>Fever<br />Erythema or purulence at line site<br />Hyperglycemia</blockquote><br /><p><strong>What are potential sources of catheter colonization and infection?</strong><br /><blockquote>1. Skin insertion site<br />2. Catheter hub<br />3. Hematogenous seeding of catheter tip from distant site<br />4. Infusate contamination</blockquote></p><br /><p>50-70% of infections are estimated to originate from the catheter hub</p><br /><p><strong>How is suspicion for catheter-related septicemia conventionally addressed?</strong><br /><blockquote>The catheter is removed and the tip is cultured after 2 paired blood cultures are drawn.<br />The catheter can be rethreaded over a guidewire while waiting for results, or one can be placed at a new site. If cultures are positive, a new catheter should be placed at a new site.</blockquote></p><br /><p><strong>What are paired blood cultures?</strong><br /><blockquote>One from the catheter hub and one from a peripheral site.<br />These may be evaluated quantitatively or semi-quantitatively</blockquote><br /><p><strong>What defines catheter tip colonization?</strong><br /><blockquote>>15 cfu grown from catheter tip<br />negative blood cultures</blockquote></p><br /><p><strong>What defines catheter-related blood-stream infection?</strong><br /><blockquote>>15 cfu grown from catheter tip<br />positive paired blood cultures with same organism (semi-quantitative)</blockquote></p><br /><p><strong>What are three methods for diagnosing catheter-related blood stream infections that do not require catheter removal?</strong><br /><blockquote>1. <u>Paired quantitative blood cultures</u> - compare bacterial growth of catheter blood with peripheral blood (catheter blood growth >5-10X peripheral)<br />2. <u>Differential time to positivity of quantitative blood cultures</u> - compare time to bacterial growth of catheter blood with peripheral blood (catheter blood growth >2hrs earlier than peripheral)<br />3. <u>Semi-quantitative superficial cultures</u> - swabs of skin and catheter hub (>15cfu) are compared with peripheral blood isolates.</blockquote></p><br /><p>In a prospective randomized controlled trial comparing the three methods in critically-ill patients without neutropenia, there were no significant differences between their diagnostic accuracy (94%, 91%, 90%). They recommended starting assessment with superficial swabbing and peripheral blood cultures as a potential way to avoid unnecessary catheter removal.</p><br /><br />Late... SG<br /><br /><u>Sources</u>:<br />Schwartz' Principles of Surgery, 8th ed.<br />O'Leary's Physiologic Basis of Surgery, 3rd ed. <br />Bouza E, Alvarado N, Alcala L, Perez MJ, Rincon C, Munoz P. A Randomized and Prospective Study of 3 Procedures for the Diagnosis of Catheter-Related Bloodstream Infection without Catheter Withdrawal. <em>Clin Infect Dis</em> 2007; 44: 820-826.<br />Linares J. Diagnosis of Catheter-Related Bloodstream Infection: Conservative Techniques. <em>Clin Infect Dis</em> 2007; 44: 827-829.Unknownnoreply@blogger.com833tag:blogger.com,1999:blog-14234389916382717.post-48922198394111921602007-03-06T20:08:00.000-05:002007-03-11T01:50:46.898-05:00Oncotype DX and Gene Expression Profiling<div align="center"><em>No, that's not a Lite-Brite... It's a DNA microarray!</em><br /><p><br /><a href="http://radio.weblogs.com/0105910/images/ecoli_dna.jpg"><em><img style="FLOAT: right; MARGIN: 0px 0px 10px 10px; WIDTH: 181px; CURSOR: hand" height="132" alt="" src="http://radio.weblogs.com/0105910/images/ecoli_dna.jpg" border="0" /></em></a></div><p align="left">Over recent years, interest has blossomed in the development of biomarkers and assays to help predict cancer outcomes. Today, we'll talk about a few of these for breast cancer, focusing on Oncotype DX (<a href="http://www.genomichealth.com/oncotype/hcphome.aspx">Genomic Health</a>).</p><br /><p><strong>What is a prognostic marker?</strong><br /><blockquote>A pathologic or molecular marker that can predict disease-free survival, disease-specific survival, or overall survival.</blockquote></p><br /><p><strong>What is a predictive marker?</strong><br /><blockquote>A pathologic or molecular marker that is used to predict response to therapy.</blockquote></p><br /><p><strong>What are some prognostic markers for breast cancer?</strong><br /><blockquote>Tumor grade<br />Hormone receptor status<br />HER2/neu status<br />Ki-67 (a proliferation marker)<br />S-Phase Fraction (a proliferation marker)<br />Mitotic Index<br />Cathepsin-D (a protease)<br />Lymphovascular invasion</blockquote></p><br /><p><strong>What are the primary prognostic determinants for breast cancer?</strong><br /><blockquote>Tumor size<br />Nodal Metastasis<br />Distant Metastasis</blockquote></p><br /><p><strong>What are some predictive markers for breast cancer?</strong><br /><blockquote>Estrogen Receptor Status<br />HER2/neu Status</blockquote></p><br /><p><strong>What is a therapeutic approach that can be used for node-positive patients with tumors that overexpress HER2/neu?</strong><br /><blockquote>trastuzumab (Herceptin, <a href="http://www.herceptin.com/herceptin/professional/index.jsp">Genentech</a>)</blockquote></p><br /><p><strong>What are some therapeutic approaches can be used for patients with tumors that are estrogen-receptor postive?</strong><br /><blockquote>Selective estrogen-receptor modulators (SERMs): tamoxifen, fulvestrant (Faslodex, AstraZeneca)<br />Aromatase inhibitors</blockquote></p><br /><p><strong>What did the clinical trial NSABP B-14 examine?</strong><br /><blockquote>NSABP B-14 demonstrated the <u>benefit of 5-years of tamoxifen as adjuvant therapy</u> for node-negative, estrogen-receptor-postive breast cancer in both survival and recurrence.<br />Patients (N0,ER+) were randomized to placebo (n=1453) or tamoxifen (n=1439).<br />Tamoxifen benefited women over placebo with hazard ratios for overall survival of 0.80 (95% CI, 0.71-0.91) and for recurrence-free survival of 0.58 (95% CI, 0.50-0.67) when followed for 15 years.</blockquote></p><br /><p><strong>What did the clinical trial NSABP B-20 examine?</strong><br /><blockquote>NSABP B-20 demonstrated the <u>benefit of tamoxifen <em>and</em> chemotherapy</u> for node-negative, estrogen-receptor-positive breast cancer by decreasing recurrences, but only a borderline effect on survival.<br />Patients (N0,ER+) were randomized to tamoxifen (n=788) or chemotherapy (CMF) and tamoxifen (n=789).<br />Tamoxifen plus chemotherapy benefited women over tamoxifen alone with hazard ratios for overall survival of 0.78 (95% CI, 0.60-1.01) and recurrence-free survival of<br />0.52 (95% CI, 0.39-0.68) when followed for 12 years. This benefit was seen primarily in patients under 60 years.</blockquote></p><br /><p>In Fisher <em>et al. Lancet</em> 2004, they reanalyzed the data for B-20 by comparing it with the placebo group of B-14. They found that there was about a 20-25% absolute benefit in recurrence-free survival with tamoxifen and chemotherapy compared to placebo.</p><br /><p>Adding chemotherapy to tamoxifen likely benefits some patients in reducing recurrences, but probably not all, with overtreatment of possibly 80% of patients based only on the criteria of node-negative, estrogen-receptor-positive...</p><br /><p>At the moment, many oncologists recommend giving both tamoxifen and chemotherapy for all ER+, node-negative tumors greater than 1cm... This may be overtreating the majority.</p><br /><p><strong>What is Oncotype DX?</strong><br /><blockquote>A gene expression assay developed for node-negative, estrogen-positive breast tumors that uses information derived from fixed, paraffin-embedded tissue specimens to develop a recurrence prediction score.</blockquote></p><br /><p><strong>Why is it nice that they use paraffin-embedded tissue specimens for the assay?</strong><br /><blockquote>You, the surgeon, do not need to think about sending fresh or frozen tissue samples at the time of surgery! The multidisciplinary team can decide at a later time after reviewing the pathology if the test will help with management.</blockquote><br /><p><strong>How is the assay performed?</strong><br /><blockquote>Quantitative RT-PCR (Reverse transcriptase polymerase chain reaction)<br />This quantifies RNA for 21 different genes to give an idea of their relative level of expression. These levels are then used in an algorithm to calculate a "recurrence score".</blockquote></p><br /><p><strong>What categories of genes are studied by this assay?</strong><br /><blockquote>5 controls and 16 cancer-related genes (derived from 250 candidates)<br />1. <u>Proliferation</u>: Ki67, STK15, Survivin, cyclin B1, MYBL2<br />2. <u>Invasion</u>: Stromolysin 3, Cathepsin L2<br />3. <u>HER2</u>: GRB7, HER2<br />4. <u>Estrogen</u>: ER, PR, Bcl-2, SCUBE2<br />5. <u>Other</u>: GSTM1, CD68, BAG1<br />6. <u>Controls</u>: beta-actin, GAPDH, RPLPO, GUS, TFRC</blockquote><p></p><br /><p><strong>How was the recurrence score developed?</strong><br /><blockquote>Based on analysis using blocks from patients in the Tamoxifen arm of NSABP B-20, they divided patients into three groups:<br />1. Low Risk<br />2. Intermediate Risk<br />3. High Risk</blockquote></p><br /><p><strong>How did they validate the assay?</strong><br /><blockquote>In Paik <em>et al. NEJM</em>, 2004, they examined available blocks from patients in the tamoxifen arm of NSABP B-14. Based on stratification of recurrence score risk categories, they were able to determine Kaplan-Meier estimates for recurrence rates.</blockquote></p><br /><strong>What were their findings for rates of distant recurrence at 10 years?</strong><br /><blockquote>Low Risk Category (51%) - 7% (95% CI, 4-10%)<br />Intermediate Risk (22%) - 14% (95% CI, 8-20%)<br />High Risk Category (27%) - 31% (95% CI, 24-37%)</blockquote></p><br /><p>The recurrence score also correlated with overall survival and relapse-free interval.</p><br /><p><strong>When performing multivariate analysis for independent predictors of recurrence in B-14, what variables were significant?</strong><br /><blockquote>Before including the recurrence score, age less than 50 years and tumor size greater than 2cm were independent predictors of recurrence.<br />After including the recurrence score, both variables dropped out, and only recurrence score remained as an independent predictor of recurrence.</blockquote></p><br /><p><strong>What treatment algorithm could be developed utilizing Oncotype DX for node-negative, ER-positive patients who will receive tamoxifen, without factoring cost and access into the issue?</strong><br /><blockquote>For low risk patients, tamoxifen only<br />For high risk patients, tamoxifen plus chemotherapy<br />For intermediate patients, tamoxifen with or without chemotherapy (i.e. depending on age, size, grade)</blockquote></p><br /><strong>What is the cost of Oncotype DX?</strong><br /><blockquote>US $3460 (as of 06 Mar 2007)<br />Medicare covers this 100%<br />A few insurances are beginning to cover this.</blockquote></p><br /><p><strong>What are some other prognostic assays creeping into the clinical mainstream?</strong><br /><blockquote>The following utilize cDNA microarray technology to classify breast tumors based on molecular signatures.<br />1. <u>70-gene profile</u> - categorizes tumors into good and poor prognostic groups<br />2. <u>Intrinsic-Subtype Signatures</u> - Categorizes breast tumors into 5 subtypes: basal-like (ER/PR-,HER2-), ER-negative/HER2-positive, luminal A, luminal B, and normal-like.<br />3. <u>Wound-Response Signatures</u> - categorizes tumors based on activated or quiescent responses</blockquote></p><br /><p><strong>What is a cDNA Microarray?</strong><br /><blockquote>Sometimes called a gene chip.<br />A test that examines the expression of numerous genes probed simultaneously. Analysis of the profile can allow categorization of tumors based on the characteristic signatures of overexpressed and underexpressed genes.</blockquote></p><br /><p><strong>What is an IVDMIA?</strong><br /><blockquote>In Vitro Diagnostic Multivariate Index Assay<br />It is the US FDA's new classification for algorithm-based gene profiling assays including Oncotype DX and Mammaprint.</blockquote></p><br /><p><strong>What is Mammaprint?</strong><br /><blockquote>Mammaprint (<a href="http://www.agendia.com">Agendia</a>) is the 70-gene-profile microarray. It recently received FDA approval on February 6, 2007, but has been marketed in Europe since 2005.</blockquote></p><br /><p><strong>How do Mammaprint and Oncotype DX differ?</strong><br /><blockquote>Oncotype DX uses quantitative RT-PCR on fixed paraffin-embedded specimens.<br />Mammaprint uses DNA microarray technology on freshly-obtained core biopsy specimens.<br />Oncotype DX is marketed for node-negative, ER-positive patients who will be starting tamoxifen to decide on starting additional adjuvant chemotherapy.<br />Mammaprint is marketed for T1/T2N0M0 patients under 60 years old to decide on type of adjuvant therapy.<br />Mammaprint was developed in the Netherlands and has been a focus of study in Europe. Oncotype DX has been developed and studied primarily in North America. </blockquote></p><br /><p>In the future, the EORTC's MINDACT trial (Microarray in Node-Negative Disease May Avoid Chemotherapy), which uses the Mammaprint 70-gene profile, will give more to think about... </p><br /><br />Phew! That's all for now... SG<br /><br /><u>Sources:</u><br />Schwartz' Principles of Surgery, 8th ed.<br />Fisher B, Jeong JH, Bryant J, Anderson S, Dignam J, Fisher ER, Wolmark N. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. <em>Lancet</em> 2004; 364: 858-868.<br /><a href="http://content.nejm.org/cgi/content/abstract/351/27/2817">Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. <em>NEJM</em> 2004; 351: 2817-2826.</a><br /><a href="http://content.nejm.org/cgi/content/short/355/6/615">O'Shaugnessy JA. Molecular Signatures Predict Outcomes in Breast Cancer. <em>NEJM</em> 2006; 355: 615-617.</a><br /><a href="http://www.agendia.com/index.php?option=com_content&task=view&id=6&Itemid=29">Mammaprint</a><br />Cost information obtained from a phone conversation with a representative from <a href="http://www.genomichealth.com">Genomic Health</a>, 1-866-ONCOTYPEUnknownnoreply@blogger.com5tag:blogger.com,1999:blog-14234389916382717.post-27162124958155228052007-02-28T17:42:00.000-05:002007-03-06T22:30:55.381-05:00Leadership<object height="350" width="425"><param name="movie" value="http://www.youtube.com/v/Z6h8gSaY_lE"><param name="wmode" value="transparent"><embed src="http://www.youtube.com/v/Z6h8gSaY_lE" type="application/x-shockwave-flash" wmode="transparent" width="425" height="350"></embed></object><br /><br />Late... SGUnknownnoreply@blogger.com2tag:blogger.com,1999:blog-14234389916382717.post-48778063607457745642007-02-26T17:50:00.000-05:002007-02-27T14:31:56.470-05:00Enteral Nutrition<a href="http://growabrain.typepad.com/growabrain/images/tv_dinner_2.jpg"><img style="FLOAT: right; MARGIN: 0px 0px 10px 10px; WIDTH: 193px; CURSOR: hand" height="164" alt="" src="http://growabrain.typepad.com/growabrain/images/tv_dinner_2.jpg" border="0" /></a><br /><p><strong>Besides providing systemic nutrition, what are the benefits of enteral nutrition?</strong><br /><blockquote>Avoids GI mucosal atrophy<br />Maintains gut-associated lymphoid tissue<br />Decreases infectious complications from bacterial translocation<br />Yields better glycemic control than parenteral nutrition<br />Less risks compared to parenteral nutrition (i.e. central venous catheter-related complications)<br />Less cost than parenteral nutrition</blockquote></p><br /><p><strong>Do all patients benefit from early enteral nutrition?</strong><br /><blockquote>No. Prospective randomized controlled trials (RCTs) show that patients with Albumin > 4g/dl undergoing GI surgery have no differences in outcome and complications when receiving enteral nutrition compared to maintenance IV solutions in the initial days following surgery.<br />However, most prospective RCTs and meta-analyses show that patients with severe abdominal or thoracic trauma have decreased infectious complications with early enteral nutrition compared to unfed or parenteral nutrition. The exception is patients with closed-head injury.</blockquote></p><br /><p><strong>What is special about head trauma patients?</strong><br /><blockquote>They are at risk for gastroparesis, with a higher risk of aspiration.</blockquote></p><br /><p><strong>What are indicators of gastroparesis?</strong><br /><blockquote>Gastric residuals >200mL over 4-6hrs<br />Abdominal distension</blockquote></p><br /><p>Consider NGT decompression and postpyloric feeding.</p><br /><p><strong>What about patients with enterocutaneous fistula?</strong><br /><blockquote>Enteral support is acceptable for low output enterocutaneous fistulas (<500 ml/day) </blockquote></p><br /><p><strong>When is a good time to institute enteral feeds?</strong><br /><blockquote>Early enteral support should be instituted following resuscitation from major trauma and patients where a prolonged postoperative recovery is anticipated.</blockquote></p><br /><p>Healthy patients with good nutritional status can tolerate 10 days on maintenance fluids before significant protein catabolism occurs.</p><br /><p><strong>Among hospitalized patients, how many present with alterations in nutritional parameters?</strong><br /><blockquote>15-65%, and once hospitalized with an obligated fast, 50-100% become undernourished!</blockquote></p><br /><p><strong>Should I start enteral feeds through a nasogastric tube?</strong><br /><blockquote>Acceptable for short-term, but has aspiration risks, and often dislodges.</blockquote></p><br /><p>Reserve for intact mental status and protected laryngeal reflexes.</p><br /><p><strong>What are problems associated with postpyloric nasojejunal tubes?</strong><br /><blockquote>They are often difficult to place, and may need assistance with fluoroscopic guidance.</blockquote></p><br /><p><strong>What is a PEG?</strong><br /><blockquote>Percutaneous endoscopic gastrostomy</blockquote></p><br /><p><strong>What are common indications for PEG placement?</strong><br /><blockquote>Major facial trauma<br />Impaired swallowing<br />Oropharyngeal or esophageal obstruction<br />Cerebrovascular disease<br />Chronic neurological disorders</blockquote></p><br /><p><strong>What are contraindications to PEG placement?</strong><br /><blockquote>Gastric neoplasm<br />Ascites<br />Coagulopathy<br />Varices<br />Abdominal Wall Defect<br />Inability to perform endoscopy or transilluminate abdominal wall</blockquote></p><br /><p><strong>What are the two techniques for PEG placement?</strong><br /><blockquote>1. <u>The Push Technique</u> - uses a Foley catheter pushed through the abdominal wall via Seldinger technique using dilators<br />2. <u>The Pull Technique</u> - uses a long tapered PEG tube pulled from the mouth through the stomach across the abdominal wall via Seldinger technique</blockquote><br /><p>PEG tubes come in sizes ranging from 16-28Fr, but 20Fr is commonly used.</p><br /><p><strong>How many surgeons are necessary to perform a PEG?</strong><br /><blockquote>Two. One to perform endoscopy, and one to place the catheter.</blockquote></p><br /><p><strong>What are the components of the "Pull Technique" for PEG placement?</strong><br /><blockquote>1. IV sedation for endoscopy, with patient placed supine.<br />2. Placement of endoscope in stomach with inspection and insufflation.<br />3. Endoscopic transillumination of upper anterior abdominal wall (usually proximal to incisura)<br />4. Depress abdominal wall where light is seen... endoscopist should visually confirm indentation.<br />5. Infiltrate skin at site with local anesthetic.<br />6. Use a #11 blade to make 5-10mm skin incision.<br />7. Place 14G needle through incision into insufflated stomach.<br />8. Allow endoscopist to position snare near the needle.<br />9. Thread guidewire through needle into the stomach, allowing endoscopist to snare the guidewire. The needle can be removed.<br />10. Once guidewire is secured, it is pulled out of the mouth along with the scope.<br />The guidewire now passes through the abdominal wall into the stomach, then proximally out the mouth.<br />11. The endoscopist will secure the tapered end of the PEG tube to the proximal end of the guidewire.<br />12. The guidewire should be pulled away from the abdominal wall, which will gradually pull the PEG tube into position in the stomach up against the anterior abdominal wall.<br />13. A securing external bolster device can be fitted against the skin to keep the tube in position.<br />14. The endoscopist should visually confirm that the PEG balloon/internal bolster is adequately positioned (snug but not tight).</blockquote></p><br /><p><strong>What are complications of PEG placement?</strong><br /><blockquote>Wound infection<br />Bleeding<br />Peritonitis / Leak<br />Bowel perforation (Transilluminate!)</blockquote></p><br /><p><strong>What is a PEGJ?</strong><br /><blockquote>Allows for postpyloric access by passing a 9-12F tube through an existing PEG via endoscopic or fluoroscopic guidance.</blockquote></p><br /><p><strong>Are systemic prophylactic antibiotics recommended for PEG placement?</strong><br /><blockquote>Yes, there is Level 1 evidence that they decrease peristomal infection rates (<a href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005571/frame.html">Cochrane review</a>)</blockquote></p><br /><p><strong>How long is it recommended that a new PEG remain <em>in situ</em> before it is changed or replaced to a button?</strong><br /><blockquote>6 weeks</blockquote></p><br /><p><strong>What are surgical options for enteral access?</strong> <blockquote>Gastrostomy<br />Jejunostomy</blockquote></p><br /><p>Can be performed open or laparoscopic, depending on ability and situation.</p><br /><p><strong>What is a Stamm Gastrostomy?</strong><br /><blockquote>A series of opposing inner and outer purse-string sutures are used to secure a Foley catheter that has been passed through the anterior abdominal wall into the stomach. The sutures are then secured to the anterior abdominal wall, ensuring that the stomach is pexied in place.</blockquote></p><br /><p><strong>What is a Witzel Jejunostomy?</strong><br /><blockquote>After placement of a purse-string suture around a red rubber catheter that has been introduced into the jejunum, a seromuscular tunnel is sewn around the catheter using interrupted Lembert stitches for about 5cm. The catheter is then fixed to the abdominal wall. This can be performed longitudinally or transversely.</blockquote></p><br /><p><strong>What is a Needle-Catheter Jejunostomy?</strong><br /><blockquote>Utilizes a 6Fr catheter that is tunneled in the seromuscular space of the intestinal wall before it enters the intestinal lumen.</blockquote></p><br /><p><strong>What are indications for surgical jejunostomy?</strong><br /><blockquote>Patients undergoing major abdominal surgery where prolonged ileus or recovery is expected, or patients who are malnourished, hypermetabolic, septic, or may be undergoing postoperative chemotherapy or radiotherapy and requiring additional nutritional support.</blockquote></p><br /><p><strong>What is the only absolute contraindication for a jejunostomy or postpyloric feeding?</strong><br /><blockquote>Distal obstruction</blockquote></p><br /><p>Patients with pancreatitis can receive postpyloric feeds!</p><br /><p><strong>What is the caloric density of most isotonic enteral formulas?</strong><br /><blockquote>1.0 kcal/ml</blockquote></p><br /><p><strong>Why do some formulas contain fiber?</strong><br /><blockquote>Fiber increases intestinal transit time<br />Fiber stimulates pancreatic lipase activity<br />Soluble fiber binds bile acid and cholesterols<br />Soluble fiber is metabolized by bacteria into short-chain fatty acids</blockquote></p><br /><strong>Why should we care about short-chain fatty acids?</strong><br /><blockquote>It is the primary fuel for the <u>colonocyte</u>!</blockquote></p><br /><p><strong>What do immune-enhancing formulas often contain?</strong><br /><blockquote>glutamine<br />arginine<br />branched-chain amino acids<br />omega3 fatty acids</blockquote></p><br /><p>They cost more, but have uncertain benefit!</p><br /><strong>Why do we care about glutamine?</strong><br /><blockquote>It is the primary fuel for the <u>enterocyte</u>!<br />Lymphocytes and macrophages also love glutamine...<br />It is a precursor to glutathione (cellular anti-oxidant)</blockquote></p><br /><p><strong>Why do we care about arginine?</strong><br /><blockquote>It has a role in up-regulating immune function and promoting wound healing.<br />It is a substrate for nitric oxide synthase.<br />It affects anabolic hormone release including growth hormone, glucagon, prolactin, and insulin.</blockquote></p><br /><p><strong>Why do we care about omega-3 fatty acids?</strong><br /><blockquote>They decrease the inflammatory response (i.e. prostaglandins)</blockquote><br /><p><strong>What is the caloric density of fluid-restriction formulas?</strong><br /><blockquote>1.5-2.0 kcal/ml</blockquote></p><br /><p><strong>What is the content of elemental formulas?</strong><br /><blockquote>Predigested nutrients</blockquote></p><br /><p>These are higher in osmolality, but considered in situations such as malabsorption, gut impairment, and pancreatitis.</p><br /><p><strong>What is bolus feeding?</strong><br /><blockquote>Delivering 200-500ml of formula over a short amount of time (i.e. 5 minutes).</blockquote></p><br /><p>This is the most physiologic, and typically only into the stomach.</p><br /><p><strong>What is intermittent feeding?</strong><br /><blockquote>Infusing a volume delivered by gravity drip over 20-30 minutes.</blockquote></p><br /><p><strong>What is continuous feeding?</strong><br /><blockquote>Enteral delivery using an infusion pump, typically over 12-24 hours.<br />Usually increased by 10-25ml/hr every 4+ hours to a desired goal rate.</blockquote></p><br /><p>Required for postpyloric feeds.</p><br /><p><strong>What are potential nasty complications of enteral feeding in the setting of global hypoperfusion?</strong><br /><blockquote>pneumatosis intestinalis and small bowel necrosis</blockquote></p><br /><p>Delay enteral nutrition until adequate resuscitation has been acheived!</p><br /><p><strong>What is "trophic" feeding?</strong><br /><blockquote>Using enteral nutrition to complement parenteral nutrition, by administering enough as tolerated to stimulate intestinal trophism, while providing primary nutritional support via TPN.<br />Used in patients who cannot tolerate full enteral nutrition.</blockquote></p><br /><br />Late... SG<br /><br /><u>Sources</u>:<br />Schwartz' Principles of Surgery, 8th ed.<br />O'Leary's Physiologic Basis of Surgery, 3rd ed.<br />Scott-Connor's The SAGES Manual: Fundamentals of Laparoscopy and GI Endoscopy (1999)<br /><a href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005571/frame.html">Lipp A, Lusardi G. Systemic antimicrobial prophylaxis for percutaneous endoscopic gastrostomy. <em>Cochrane Database of Systematic Reviews</em> 2006, 4 :CD005571.</a><br />Tapia J, Murguia R, Garcia G, de Los Monteros PE, Onate E. Jejunostomy: Techniques, Indications, and Complications. <em>World J Surg</em> 1999; 23: 596-602.<strong></strong><strong></strong>Unknownnoreply@blogger.com1tag:blogger.com,1999:blog-14234389916382717.post-2363435978717744282007-02-23T22:56:00.000-05:002008-12-08T21:23:09.888-05:00Cold Injury<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhJ1pxMhe3le9GJvEB3UrEIOETcciCjxj71NfcvqhvKF0BQCPqD6jJl-h_f-2OwBiBMKuZIpRCHA0GCCQ6QfRSDng1fmlI3JHvDM7IyPmwQtRzAtz9uJs6_z38PQjE1jTHpoOqFGr-PLdQ/s1600-h/Cold.jpg"><img style="float:right; margin:0 0 10px 10px;cursor:pointer; cursor:hand;" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhJ1pxMhe3le9GJvEB3UrEIOETcciCjxj71NfcvqhvKF0BQCPqD6jJl-h_f-2OwBiBMKuZIpRCHA0GCCQ6QfRSDng1fmlI3JHvDM7IyPmwQtRzAtz9uJs6_z38PQjE1jTHpoOqFGr-PLdQ/s320/Cold.jpg" border="0" alt=""id="BLOGGER_PHOTO_ID_5072066988709882690" /></a><br /><br /><p><strong>What is frostnip?</strong><br /><blockquote>A mild form of cold injury that is reversible, characterized by numbness, pain, and pallor. Frequent on exposed digits, ears, and nose.</blockquote></p><br /><p><strong>What is frostbite?</strong><br /><blockquote>Irreversible tissue damage caused by ice crystal formation leading to cellular death. Characterized by initial tissue freezing injury, followed by reperfusion injury during rewarming.</blockquote></p><br /><p><strong>How is frostbite severity graded?</strong><br /><blockquote><u>First degree</u>: No blistering; tissue is frozen with hyperemia and edema<br /><u>Second degree</u>: Frozen tissue with hyperemia, edema, and large, clear blisters<br /><u>Third degree</u>: Death of subcutaneous tissues and skin leading to small, hemorrhagic blisters<br /><u>Fourth degree</u>: Necrosis, gangrene, and full-thickness tissue loss. </blockquote></p><br /><p><strong>What are chilblain and pernio?</strong><br /><blockquote>Terms describing local cold injury characterized by pruritic skin lesions on the face, anterior surface of the tibia, or dorsum of the hands and feet.<br />Associated with a chronic vasculitis of the dermis, provoked by repeated exposure to cold (not freezing) temperatures.<br />Can be managed with antiadrenergics or calcium channel blockers.</blockquote></p><br /><p><strong>What is trench foot?</strong><br /><blockquote>Nonfreezing injury to hands or feet caused by chronic exposure to wet conditions just above freezing. Involves alternating vasospasm and vasodilatation leading to eventual ulceration.</blockquote></p><br /><p><strong>What is the management of frostbite?</strong><br /><blockquote>1. Remove patient from cold environment. Do not rub or exercise the extremity.<br />2. Manage ABCs, addressing systemic hypothermia and fluid resuscitation.<br />3. Rapidly rewarm tissue by immersion in a warm water bath of 40-42 degrees C.<br />4. Provide narcotic analgesia as necessary.<br />5. Address tetanus status.<br />6. Cleanse and dry skin of affected area.<br />7. Keep affected extremity elevated to minimize edema, with cotton between digits to prevent maceration.<br />8. Consider angiography and thrombolytic therapy<br />9. Allow demarcation of tissue necrosis.<br />10. Monitor for compartment syndromes during the rewarming phase</blockquote></p><br /><p><strong>When is amputation and surgical debridement recommended?</strong><br /><blockquote>Delayed for 2-3 months, unless tissue becomes infected or sepsis intervenes. </blockquote></p><br /><p>Often, permanent tissue loss is less than expected. <br />"...of all the factors in the treatment of frostbite that may influence outcome, premature surgical intervention by any means, in any amount, was by far the greatest contributor to poor results."</p><br /><p>Allow the devitalized tisue to demarcate!</p><br /><p><strong>Besides tissue necrosis, what are some skin complications after frostbite?</strong><blockquote>Hyperhidrosis<br />Neuropathy<br />Decreased nail and hair growth<br />Persistent Raynaud's phenomenon</blockquote></p><br /><br />Late... SG<br /><br /><u>Source</u>:<br />Jurkovich GJ. Environmental Cold-Induced Injury. <em>Surg Clin N Am</em> 2007; 87: 247-267.Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-14234389916382717.post-26900865559125245842007-02-22T23:24:00.000-05:002007-02-23T02:13:06.131-05:00Hypothermia and Drowning<object width="425" height="350"><param name="movie" value="http://www.youtube.com/v/p6D4Lmj2yeY"></param><param name="wmode" value="transparent"></param><embed src="http://www.youtube.com/v/p6D4Lmj2yeY" type="application/x-shockwave-flash" wmode="transparent" width="425" height="350"></embed></object><br /><br /><p>Grey's Anatomy (ABC) has recently presented a series of episodes that has examined the management of a situation of mass casualty. However, in a plot twist that has been milked for a couple weeks, our heroine, Dr. Meredith Grey, had been pushed into the Pacific Ocean after skillfully tying off a major vessel in a trauma patient, tourniquet unnecessary. After rescue from drowning by her dashing suitor, Dr. Derek 'McDreamy' Shepherd, she now presents to good old Seattle Grace... hypothermic and unresponsive. <em>What ever shall we do?</em></p><br /><p>Remember, a moist, cold Meredith isn't dead... until she's warm and dead.</p><br /><p><strong>Are there any recommendations for how to remove a drowning victim out of the water?</strong><br /><blockquote>It has been suggested that patients be lifted in the prone position.</blockquote></p><br /><p>Immersion in water results in an increase in cardiac output due to decreased resistance to flow. Removing a person from water in an upright position can cause venous pooling from circulatory collapse that is attributed to deaths seen within minutes of rescue in responsive patients.</p><br /><p><strong>What measures should be done at the scene of a drowning victim?</strong><br /><blockquote>Wet clothing should be removed and the patient wrapped in thick blankets.<br />Don't waste time rewarming patient.<br />Transfer patient to facility that has available extracorporeal rewarming.<br />Intubate the patient if unconscious.<br />Continuous chest compressions should be applied for cardiopulmonary arrest.<br />Protect C-spine</blockquote></p><br /><p><strong>What about defibrillation at the scene?</strong><br /><blockquote>When the myocardium is cold, this will be ineffective...</blockquote></p><br /><p><strong>What factors have favorable outcomes with near drowning?</strong><br /><blockquote>Submersion less than 5 minutes<br />Heart beat that is restored immediately<br />Immersion in ice cold water (less than 5 degrees C)<br />Buoyancy devices decrease aspiration risk</blockquote></p><br /><p><strong>What factors have possible complications?</strong><br /><blockquote>Fresh water causes more V/Q mismatch than salt water<br />River water causes potential risk of infection (leptospirosis)<br />Shallow water raises possibility of fractures</blockquote></p><br /><p><strong>What is hypothermia?</strong><br /><blockquote>Core body temperature below 35 degrees C<br /><u>Mild</u>: 32-35 degrees C (89.6-95.0 F)<br /><u>Moderate</u>: 28-32 degrees C (82.4-89.6 F)<br /><u>Severe</u>: <28 degrees C (<82.4 F)</blockquote></p><br /><p><strong>What is primary hypothermia?</strong><br /><blockquote>Decrease in core temperature from environmental stress</blockquote></p><br /><p><strong>What is secondary hypothermia?</strong><br /><blockquote>Unintentional hypothermia from abnormal thermoregulation.<br />Risk factors include age, hypothyroidism, hypoadrenalism, trauma, hypoglycemia, anesthetics.</blockquote></p><br /><p><strong>Below what temperature is shivering abolished?</strong><br /><blockquote>Somewhere between 30-33 degrees C.</blockquote></p><br /><p><strong>What happens to the cardiac conduction system with moderate to severe hypothermia?</strong><br /><blockquote>Below 30 degrees C atrial fibrillation, bradycardia, and ventricular dysrhythmias become common.<br />Below 25 degrees C asystole occurs.</blockquote></p><br /><p><strong>What is the eponym attributed to hypothermia-related gastric erosions?</strong><br /><blockquote>Wischnevsky's ulcers</blockquote></p><br /><p><strong>What does mild, postoperative hypothermia do to surgical wound infection rates?</strong><br /><blockquote>-1.9 degrees C core hypothermia triples the incidence of SSIs and increases the hospital stay by 20%</blockquote></p><br /><p><strong>What is the mortality rate for trauma patients with moderate primary hypothermia?</strong><br /><blockquote>Approximately 20%</blockquote></p><br /><p><strong>Does intentional hypothermia (32-33 degrees C) protect against severe traumatic brain injury?</strong><br /><blockquote>No. A multicenter randomized clinical trial for GCS 3-7 patients showed no difference in mortality (28% vs. 27%) and greater hospital days and complications when comparing 48hrs of intentional hypothermia with normothermia.</blockquote></p><br /><p><strong>Does intentional hypothermia protect against complications of cardiac arrest?</strong><br /><blockquote>Yes. A prospective multicenter randomized clinical trial of patients in ventricular fibrillation found cooled patients had better neurologic outcomes (55% vs 39%), lower mortality (41% vs 55%), but higher rates of bleeding, sepsis, and pneumonia.</blockquote></p><br /><p><strong>What is the triad of death?</strong><br /><blockquote>Acidosis, Hypothermia, and Coagulopathy</blockquote></p><br /><strong>How does hypothermia cause coagulopathy?</strong><br /><blockquote>1. Decrease in clotting factor enzymatic function<br />2. Qualitative platelet dysfunction</blockquote></p><br /><p><strong>What is passive external rewarming?</strong><br /><blockquote>Allowing the ambient air to spontaneously warm the patient.</blockquote></p><br /><p><strong>What is active external rewarming?</strong><br /><blockquote>Placing blankets, heating pads, bair huggers, or applying heat lamps on the patient<br />Immersing the patient in warm water</blockquote></p><br /><p><strong>What are methods of active core rewarming?</strong><br /><blockquote>Heated intravenous fluids<br />Heated bladder, gastric, or colonic lavage<br />Heated peritoneal or thoracic lavage<br />Heated humidified inhaled air<br />Extracorporeal circulatory rewarming</blockquote></p><br /><p><strong>What maximum temperatures are safe for intravenous rewarming?</strong><br /><blockquote>Blood heated to 42 degrees C<br />Crystalloids heated to 65 degrees C</blockquote></p><br /><p><strong>What are methods of extracorporeal circulatory rewarming?</strong><br /><blockquote>1. Cardiopulmonary bypass<br />2. CAVR - continuous arteriovenous rewarming</blockquote></p><br /><p><strong>What is a limitation of cardiopulmonary bypass?</strong><br /><blockquote>The need for systemic anticoagulation</blockquote></p><br /><p><strong>What does CAVR involve?</strong><br /><blockquote>Connecting the patient to a counter-current heat exchange circuit but relying on the intrinsic cardiac pump</blockquote><br /><p><strong>How much effort does it take to warm a 70kg patient by 1 degree C?</strong><br /><blockquote>Using 41 degree C humidified inspired air - more than 6 hours<br />Using 44 degree C body cavity lavage - 14 L of fluid<br />Using 40 degree C extracorporeal rewarming - 10 times faster than lavage</blockquote></p><br /><p><strong>What is the pathophysiology of "rewarming shock"?</strong><br /><blockquote>Peripheral rewarming results in peripheral vasodilatation. In the absence of adequate volume resuscitation this will result in decreased cardiac output.</blockquote></p><br /><p><strong>What is "afterdrop"?</strong><br /><blockquote>A decrease in core central temperature after cold peripheral blood returns to circulation secondary to vasodilation from rewarming measures. </blockquote></p><br /><br />Late... SG<br /><br /><br /><u>Sources</u>:<br />Harries M. Near drowning. <em>BMJ</em> 2003; 327: 1336-1338.<br />Jurkovich GJ. Environmental Cold-Induced Injury. <em>Surg Clin N Am</em> 2007; 87: 247-267.<strong></strong>Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-14234389916382717.post-17244581970642603052007-02-18T18:10:00.000-05:002007-02-18T23:03:52.070-05:00Abdominal Compartment Syndrome<p><strong>What are factors posing a risk for abdominal compartment syndrome?</strong><br /><blockquote>Major trauma; damage control<br />Extensive burns<br />Large volume fluid resuscitation<br />Bowel distension from ileus, obstruction, or third spacing<br />Closure of abdomen under tension<br />Ischemia-reperfusion injury<br />Coagulopathy</blockquote></p><br /><p><strong>What is abdominal compartment syndrome?</strong><blockquote>Intra-abdominal hypertension associated with end-organ dysfunction.</blockquote></p><br /><p><strong>What are the three clinical findings associated with abdominal compartment syndrome?</strong><blockquote>1. Hypotension<br />2. Oliguria<br />3. Elevated peak airway pressures</blockquote></p><br /><p><strong>What is the pathophysiology of abdominal compartment syndrome?</strong><blockquote>-Intra-abdominal hypertension decreases venous return and stroke volume, while increasing afterload, leading to a decrease in cardiac output.<br />-Decreased renal blood flow and GFR stimulates the renin-angiotensin-aldosterone system. However, direct renal vascular compression may lead to oliguria not responsive to volume.<br />-The diaphragm is displaced, decreasing TLC and FRC and increasing inspiratory pressures.<br />-Mesenteric flow decreases leading to splanchnic venous congestion, bowel mucosal edema, and acidosis.</blockquote><br /><p><strong>What is intra-abdominal hypertension?</strong><br /><blockquote>Intra-abdominal pressures greater than 10 mmHg</blockquote></p><br /><p><strong>In the setting of intra-abdominal hypertension, what happens to CVP and PCWP readings?</strong><br /><blockquote>Both appear elevated, even though the patient may have intravascular volume depletion.</blockquote></p><br /><strong>What is a grading system used for intra-abdominal hypertension?</strong><br /><blockquote><u>Grade I</u> 10-15 mmHg - Maintain euvolemia<br /><u>Grade II</u> 15-25 mmHg - Volume expansion, may need surgery<br /><u>Grade III</u> 25-35 mmHg - Consider abdominal decompression<br /><u>Grade IV</u> >35 mmHg - Needs abdominal decompression with re-exploration</blockquote></p><br /><p>Signs of abdominal compartment syndrome usually do not manifest until Grade II intra-abdominal hypertension (greater than 15 mmHg or 20 cmH2O).</p><br /><p><strong>How do you measure abdominal pressures?</strong><br /><blockquote>The most common surrogate is the measurement of bladder pressures.<br />1. Inject 50mL NS into the aspiration port of a Foley catheter.<br />2. Place an occlusive clamp distally, or use a 3-way stopcock.<br />3. Insert a needle into aspiration port and connect to a CVP manometer.<br />4. Zero the manometer at the pubic symphisis.</blockquote></p><br /><p>Note that different publications report their units in cmH2O (direct measurement of height of column of water) or mmHg (what most CVP manometers will read). The conversion factor is 1 mmHg = 1.36 cmH2O.</p><br /><p><strong>What are two independent predictors for the development of abdominal compartment syndrome in non-trauma surgical patients?</strong></p><br /><blockquote>1. Elevated peak airway pressures<br />2. Positive 24-hr fluid balance</blockquote></p><br /><p><strong>When is abdominal decompression generally recommended?</strong><br /><blockquote>1. IAP greater than 20mmHg with UOP less than 0.5ml/kg/h, peak airway pressure greater than 45 cmH2O, and DO2 less than 600ml/min/m2.<br />2. IAP greater than 25mmHg.</blockquote></p><br /><p>There are no hard and fast rules here, but avoid signs of organ dysfunction!</p><br /><p><strong>What are outcomes of abdominal decompression?</strong><br /><blockquote>80% of patients have improvement in organ function.<br />Overall there is a mean survival rate of 53% (reports of 17-75%)!</blockquote></p><br /><p><strong>Are there methods to prevent abdominal compartment syndrome?</strong><br /><blockquote>Avoid primary fascial closure after damage control laparotomy or if the patient is at high risk at the time of the index operation.<br />-Temporary towel clip closure<br />-Prosthetic mesh closure<br />-Vacuum-assisted closure device</blockquote></p><br /><p><strong>What are some methods of dealing with an open abdomen after decompressive laparotomy?</strong><br /><blockquote>1. Bogota bag - suture sterile irrigation bag to the skin to protect abdominal viscera<br />2. Pack abdomen with saline gauze then cover with Ioban, with or without sump drains<br />3. Prosthetic mesh closures (some have built-in zippers or velcro)<br />4. Vacuum-assisted closure devices</blockquote></p><br /><p>Protect the fascia if possible so it can be saved for definitive closure!</p><br /><br />Late... SG<br /><br /><u>Sources</u>:<br />Schwartz' Principles of Surgery, 8th ed.<br />Moore AFK, Hargest R, Martin M, Delicata RJ. Intra-abdominal hypertension and the abdominal compartment syndrome. <em>Br J Surg</em> 2004; 91: 1102-1110.Unknownnoreply@blogger.com0tag:blogger.com,1999:blog-14234389916382717.post-54156509227381862152007-02-17T22:13:00.000-05:002007-02-18T00:37:01.365-05:00Exploratory Surgery<p><object height="350" width="425"><param name="movie" value="http://www.youtube.com/v/agAABAcTTGM"><param name="wmode" value="transparent"><embed src="http://www.youtube.com/v/agAABAcTTGM" type="application/x-shockwave-flash" wmode="transparent" width="425" height="350"></embed></object><br /></p><p>Watch out for colon darts... SG<br /></p>Unknownnoreply@blogger.com0